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Abstract 
 
The intersection of materials science, biology, and nanotechnology has allowed for the 
development of advanced nanobiomaterials for tissue engineering and drug delivery. With more 
knowledge of how physical and chemical properties of a biomaterial influence cell function and 
response, it is important to impart different characteristics to materials with which cells will 
interact. Characteristics to consider for tissue engineering and/or drug delivery applications 
include: biocompatibility, mechanical properties, surface area, and ligand presentation. As 
foreign materials that are placed into the body and are not necessary permanently, these materials 
should also be biodegradable. Previous biomaterials have fallen short in many ways (i.e. lack of 
degradability, poor modulus matching, lack of porosity), as it is difficult to design a material 
with all necessary attributes. The more biomimetic and tailorable a material is, the better suited it 
is for these applications. New chemistries and approaches must be considered to incorporate all 
necessary characteristics. This work introduces two new materials that are characterized and 
evaluated for biomaterials applications and successfully overcome the temporal and spatial 
shortcomings of previous research. 
 2-methylene-1,3,6-trioxocane (MTC) is a hydrophobic monomer that is crosslinked with 
poly(ethylene glycol) diacrylate, a hydrophilic crosslinker, at varying crosslinker concentrations 
and molecular weights. In this work, with respect to tissue engineering, the materials‘ 
morphological changes, swelling, degradation, and elastic modulus properties are all assessed. 
Tunability is found in these properties as the crosslinker is adjusted and a hydrophobic-
hydrophilic balance dictates many behavioral properties, including an atypical increase in 
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swelling as crosslinker concentration is increased. The biocompatibility is assessed with MTC 
formulations with 575 Da and 2 kDa crosslinker at 1.0% crosslinker concentrations exhibiting 
moderate swelling (<100%) and modulus of ~100 kPa showing good biocompatibility and utility 
for soft tissue engineering applications. 
As a drug delivery system (DDS), crosslinked MTC samples were evaluated in terms of 
tunability and kinetics of drug release behavior. Drug release was tested for three different types 
of drugs: small molecule hydrophobic, small molecule hydrophilic, and a protein. From the 10-
week studies, MTC hydrogels importantly demonstrated suitability for controlled release of the 
small molecule hydrophobic drug, with constant zero order kinetics displayed across crosslinker 
variations at physiological pH; the model protein, exhibited first order behavior and increasing 
drug release as crosslinker concentration increases. Rapid, 1 minute subcutaneous in situ gelling 
was also demonstrated in a mouse, making MTC advantageous as an injectable DDS. 
Finally, polymeric nanoparticle functionalization is explored to improve drug 
targeting/internalization to treat HER2+ breast cancer. This strategy is tested by (1) comparing 
nanoparticles fabricated from a linear PEGMA-PLGA copolymer versus a novel palm-tree 
PEGPET-PLGA copolymer chemistry and (2) testing a new targeting peptide sequence and its 
modified targeting-internalization sequences through the addition of the TAT cell penetrating 
peptide sequence. Through early experiments, more than 2 times the binding affinity was 
measured in vitro for multi-functionalized nanoparticles compared to linear nanoparticles, 
showing that the increased peptide presentation on the nanoparticles‘ surface fabricated with the 
PEGPET-PLGA copolymer helps enhance cell targeting. Select combination peptide sequences 
with TAT also show evidence of increased HER2+ affinity.  
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From this thesis, contributions are made to the field of biomaterials by not only providing 
new materials and chemistries available for varied biomaterials use, but most critically, provides 
commentary on their necessity, methods to modulate these nanobiomaterials temporally and 
spatially and appropriate characterization, and their ongoing use. 
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Chapter 1. Introduction to Nanobiomaterials in Tissue Engineering and Drug Delivery 
 
1.1. Necessity of nanobiomaterials in the field of medicine 
The merging of the fields of biology, materials science, and nanotechnology has led to the advent 
of numerous solutions and strategies particularly in the field of medicine over the past few 
decades
(1)
. These traditional disciplines combined have formed the multidisciplinary area of 
nanobiomaterials
(2)
. Through nanobiomaterials approaches such as surface patterning techniques, 
biosensor fabrication, and nanoparticle development, strategies have been pursued that span the 
areas of prevention, diagnosis, treatment, and repair of numerous diseases and various injuries or 
defects sustained to the body. For this reason nanobiomaterials, or nanotechnology-derived 
biomaterials, encompasses a wide range of biomedical applications including their use for organ 
regeneration through a tissue engineering approach, as materials in drug delivery systems, and as 
nanomaterials used for medical imaging and sensing within the body. The ability to manipulate 
materials on this small scale, temporally and spatially, is extremely important in the applications 
listed, and a unifying focus of the work explored in this dissertation. Development of such ability 
is desired in order to fabricate improved materials, continue to advance the field, and produce 
results that are biomimetic. Manipulating materials can be approached in numerous ways, which 
generally include (1) spatial modifications through altering the surface topography, nanofeatures, 
mechanical properties, surface area/ processability, and adding functionalization, and (2) 
temporally by controlling the rate at which a material degrades or how slowly or quickly drug a 
drug is released, for example. Within the field, there is the need to continue developing and 
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advancing materials in these ways mentioned as new opportunities in nanobiomaterials can be 
achieved as the limitations of nanotechnology are surpassed. 
Nanobiomaterials are defined in the literature as materials that support or aid biological 
function in the body with structures or components that are at the nanoscale (1-100nm) in at least 
one dimension or component, although less than 1000 nm is still classified as being on the 
nanoscale
(1,3–5)
. Materials at this size range are of interest because they exhibit a number of 
properties that differentiate them from larger bulk materials and make them advantageous for use 
in tissue engineering and drug delivery. These advantageous properties include: (1) greater 
homogeneity and purity in overall material composition and structure as reactions are taking 
place on the nanoscale, (2) a significant increase in surface area which allows for greater surface 
reactivity in both larger scaffold materials and smaller nanoparticles, (3) improved mechanical 
properties in overall bulk materials (i.e. high ductility and high yield strength of scaffolds and 
substrates) due to characteristics of their composition (i.e. increased grain boundary sliding and 
short-range diffusion), and (4) superior magnetic, optical, and electrical properties also due to the 
structural composition of a material
(1)
. With regard to their use as biomaterials, nanomaterials 
offer other characteristics that are not only beneficial but also necessary for superior interaction 
and performance in biological environments with cells and tissues. The first attractive 
characteristic of nanobiomaterials is that their chemical and structural compositions are able to 
show strong similarities to nanoscale hierarchical components of natural tissues, organs, and 
cells. For example, nanomaterials made from bio-based polymers for bone tissue engineering 
have been engineered to contain calcium phosphate, collagen, and glycosaminoglycans (GAGs), 
which are all components that help the scaffold mimic the nanostructure of native bone
(6–8)
. 
Similar examples can be found across multiple tissue types including: cartilage, skin, and cardiac 
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tissue among others
(9–12)
. Another attractive characteristic of nanobiomaterials is the ability to 
tailor the features or components of the materials to a size comparable to the biomolecules and 
structures being mimicked in the fabricated microenvironment. For example, nanofibrous 
scaffolds and microspheres have been developed and used for drug delivery and tissue 
engineering applications to enhance the growth of bone and cartilage tissues
(13–15)
. The fibers that 
comprise these drug delivery devices and cell carriers have fibers that range in size from 50-
500nm in diameter and have been found to improve cell attachment as well as stimulate cell 
proliferation and differentiation. This phenomenon is hypothesized to take place because of how 
the fibers are able to recapitulate the extracellular matrix (ECM) architecture and promote 
advantageous cell-matrix interactions
(14)
. Finally, understanding the chemical and physical 
properties of nanomaterials allows them to be tailored to have specific physical and surface 
properties, providing the necessary spatial control needed to develop nanobiomaterials to which 
cells and the body respond well. Previous researchers have shown that the stiffness or rigidity of 
biomaterials can affect cell response and that the presence of different topographies and 
functional groups on the material surface can affect cell behavior and response
(16–19)
.  
 While the detailed mechanisms of interaction between nanomaterials and biological 
systems, namely cells and tissues, are currently still being investigated, it is generally accepted 
that materials‘ surface and bulk properties dictate cell and tissues responses in vitro and in 
vivo
(1,12,20)
. The greatest take away for the field, and one that highlights the importance of 
nanobiomaterials and the continued work presented in these chapters, is that to be effective, 
biomaterials must incorporate physical and chemical properties that ultimately mimic native 
tissue, enhance cell interaction, or helps control the cell microenvironment in a temporal 
manner
(21)
. The types and ways in which nanobiomaterials have been used for biomaterial 
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applications for tissue engineering and drug delivery purposes are presented in the remainder of 
this chapter.     
 
Part 1: 
1.2. Nanobiomaterials for tissue engineering 
The field of tissue engineering has developed as a way to overcome issues that are faced when 
tissues and organs must be replaced and/or repaired due to age, disease, or trauma. In general, the 
majority of organs and tissues within the human body innately face limited regenerative 
potential
(22)
. While some organs can self-regenerate, overtime as people age, cells and tissues 
often lose the ability to self-repair as the population and quality of progenitor stem cells 
decreases, limiting the healing capacity of tissues. Along the same lines, individuals who suffer a 
traumatic injury or develop a disease may necessitate tissue engineering or regenerative medicine 
approaches to heal certain defects
(21,23)
. Organ transplantation allows for damaged or diseased 
organs to be replaced by healthier organs, but this of course requires a donor organ or donor 
tissue, which is not always readily available. Organ transplantation also often commits patients 
to taking life-long immunosuppressants and carries the risk complications if the organ does not 
perform well after surgery
(24,25)
. Tissue engineering approaches aim to apply ―the principles of 
engineering and of life science towards the development and biological substitutes that restore, 
maintain, or improve tissue or organ function‖ (24). 
Tissue engineering, often interchangeably called regenerative medicine, involves the use 
of three major components, which are: (1) isolated cells, usually stem cells, to replace those that 
no longer function, (2) specific growth or differentiation factors to induce stem cells toward the 
desired tissue lineage, and (3) a three-dimensional, porous scaffold
(26–28)
. These components 
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altogether have been called the tissue engineering triad (Figure 1.1). Many factors must be 
considered when choosing the appropriate cells and biological chemicals/ cues to include in a 
tissue engineering system; this dissertation, however, focuses on the different nanobiomaterials 
and novel biomaterials approaches that have been and continue to be developed for tissue 
engineering. 
 
Figure 1.1: Components of tissue engineering triad. 
 
Tissue engineering scaffolds, as the name implies, are materials that provide support for 
growing cells and act as a template for tissue formation. Scaffolds may be seeded with cells and/ 
or growth factors and cultured in vitro to allow for tissue growth in a dish or a more dynamic 
environment, such as a bioreactor, and subsequently implanted into the body; scaffolds can also 
be directly implanted in vivo with or without cells or growth factors to use the body‘s own 
mechanisms to support tissue growth
(27)
. The type of tissue that is being regenerated and whether 
it is a soft tissue or hard tissue dictates the type of nanobiomaterial that is appropriate as a 
scaffolding material, with a poor choice in material being detrimental to the expected tissue‘s 
growth. Scaffolding materials can be made from natural or synthetic materials and range from 
Tissue 
Engineering 
Cells 
Scaffolds 
Biological 
factors 
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self-assembled structures (i.e. peptides and polyelectrolyte multilayer assemblies), to polymers, 
ceramics, metals, semiconductors, and carbon nanostructures
(1)
. Polymers are arguably the most 
versatile of all these material types, and their versatility as a material to fabricate 
nanobiomaterials for tissue engineering and drug delivery (Part 2) is discussed here. An 
overview of common polymers used to develop tissue engineering scaffolds and scaffold design 
requirements and methods is presented in the next section.   
 
1.2.1. Spatial and temporal requirements and fabrication of polymeric tissue engineering 
scaffolds 
When considering 3D polymer scaffolds and the polymers that are ideal for their fabrication, 
there are multiple design requirements that should be incorporated to engineer the optimal tissue 
engineering substrate
(27,28)
. The first requirement is that the scaffold architecture must be 
considered and the scaffold must have high porosity with adequate pore size and 
interconnectivity. Porosity allows for cell migration throughout the scaffold and eventually cell 
proliferation and tissue formation. This is important whether cells are first seeded onto the 
scaffold in vitro or the scaffold is implanted in vivo and native cells are left to attach and move 
throughout the scaffold to form new tissue, blood vessels (vascularization), and nerves. Pores 
also allow for nutrient and waste exchange throughout the scaffold, which is critical for cell and 
tissue survival. The next requirement is that scaffolds should have high surface area; the nature 
of 3D porous scaffolds allows them to readily fulfill this requirement. A high surface area is 
critical as cells must attach to a surface in order to survive and many developing tissues require a 
high cell number and good cell-cell contact for survival and growth, which can only be achieved 
through a high surface area structure. As new tissue needs to form in the place of the scaffold, 
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the third requirement is biodegradability. Scaffolds must degrade at a suitable rate to match 
tissue formation so as not to inhibit tissue growth and extracellular matrix formation. If the 
scaffold degrades too slowly tissue formation will be prevented, and a scaffold which degrades 
too rapidly leads to a lack of cell guidance. An additional aspect of this requirement is that the 
intact scaffold and the degradation by-products should have good biocompatibility. This means 
that all components and degradation products should be non-toxic and should not interfere with 
the function of any organs or be adversely immunoreactive. The final requirement, and one that 
is difficult to achieve, is developing a scaffold with good mechanical properties that mimic the 
tissue that is being replaced. The scaffold should be mechanically sound to allow for easy 
handling and implantation, have good mechanical integrity which can be difficult to maintain 
once pores are introduced into the substrate, and have a modulus that matches that of the native 
tissue being regenerated. As was alluded to previously, substrate stiffness and how proteins and 
cells are able to interact with the scaffold affect proliferation and differentiation
(29,30)
. Finally, as 
it pertains to the future of tissue engineering and translation of materials into the clinic, it should 
be possible to scale-up the production of scaffolds made at the bench and this process should be 
cost-effective. Along with this, the length and ease of storage and whether off-the shelf 
availability is possible should be considered. By meeting all of these design criteria, scaffolds 
should allow for good cell adhesion, growth, migration, and differentiation leading to the 
formation of stable and healthy tissues. 
Many natural and synthetic polymers and polymeric blends of both types of polymers are 
able to satisfy all of the requirements discussed above, especially synthetic polymers. The most 
commonly used synthetic polymers in tissue engineering are linear aliphatic polyesters, namely 
poly(glycolic acid) (PGA), poly(lactic acid) (PLA), and copolymers of both called poly(lactic-
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co-glycolic acid) (PLGA)
(28,31)
. Synthesized through the ring-opening polymerization of cyclic 
dimers, these polymers are recognized as biocompatible and degrade via hydrolysis into 
components, lactic acid and/ or glycolic acid, that the body is able to process. These polymers 
are also Food and Drug Administration (FDA) approved, which makes them ideal for clinical 
use. PGA has the simplest chemical structure and is the most hydrophilic, which makes its 
degradation rate rather short, ranging 2-4 weeks, depending on the molecular weight. PLA, 
which varies from PGA by the presence of a pendant methyl group, is more hydrophobic and 
therefore undergoes hydrolysis less readily than PGA and can take months to years to degrade 
also depending on the molecular weight. The copolymer of PGA and PLA, PLGA, is often used 
to achieve intermediate degradation rates. Different ratios of glycolic acid and lactic acid are 
used in the copolymer (i.e. 85:15, 75:25, 50:50, 25:75, and 15:85) in order to achieve an ideal 
degradation rate as well as mechanical properties when developing a scaffolding material. The 
degradation rate of these copolymers is a balance between two factors, (1) the hydrophobicity 
and hydrophilicity and (2) the stereoregularity/ crystallinity of the copolymer, which is disrupted 
when different repeated units are introduced
(28)
. Other linear aliphatic polyesters that are 
biocompatible and biodegradable are used in the field, such as polycaprolactone (PCL), 
poly(hydroxybutyrate) (PHB), and poly(glycerol sebacate) (PGS). PCL is a semicrystalline 
polymer with a very low glass transition temperature of -62°C and is therefore always in a 
rubbery state. PHB is produced via fermentation and is a highly crystalline and brittle polymer. 
Both PCL and PHB degrade at significantly slower rates than PGA, PLGA, and PLGA on the 
timescale of years, which makes them less attractive for use in developing tissue engineering 
scaffolds. PGS, on the other hand, is a polyester synthesized via a two-step polycondensation and 
cross-linking reaction of glycerol and sebacic acid, two inexpensive and FDA approved 
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components. The mechanical properties of PGS can be tuned by changing the curing time, curing 
temperature, and component concentrations. Unique from all of the polymers mentioned, PGS 
exhibits thermoset elastomeric properties, which makes it particularly useful for soft tissue 
applications
(31)
. However, it is difficult to solubilize in traditional organic solvents and a 
challenge to process due to its tackiness, which makes it not ideal for scaffold fabrication
(32)
.  
Besides meeting the requirements of biocompatibility, biodegradability, and mechanical 
tunability through composition changes, the synthetic polymers mentioned can be processed into 
3D porous scaffolds. One of the ways in which 3D scaffolds are made is using 3D printing. In 
3D printing, a computer-assisted-design (CAD) file is prepared and used to directly print 
structures made from biodegradable polymers. Multiple layers of polymer are printed and they 
are bound together using an added binding material. While very attractive as a technique and 
advantageous in the precise control and reproducibility provided, 3D printing is limited in the 
size of features that can be produced which is limited to hundreds of micrometers as there is a 
pixel/ resolution limit. Smaller features have been printed using two-photon laser printing where 
an infrared laser polymerizes precise areas in a monomer solution that is mixed with a 
photoinitiator. While this laser technique provides good resolution on the nanometer scale, this 
technology is still rather costly due to the specialized equipment needed. This laser technique 
also has limited materials selection and produces heterogeneity within the structure due to ranges 
in the materials‘ particle size. Another alternative method for creating complex 3D scaffolds 
involves patterning through lithography
(33)
. This technique, however, faces the same limitations 
as 3D printing as far as equipment needed, resolution, and scaffold heterogeneity.  
Creating interconnected, porous scaffolds has been done using a widely used reverse 
fabrication process originally developed in the Ma lab. In this process, a porogen is used to 
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create interconnected spherical pores
(34–37)
. Paraffin spheres, followed by sugar spheres that 
decrease the process time and eliminates the need for organic solvents during the porogen 
dissolution step, are produced and put into a 3D mold where they are then slightly melted 
together through a heat treatment process. Polymer is then cast into the paraffin or sugar 
template. Once the polymer is set, the porogen-polymer construct is put into an organic solvent 
or distilled water to dissolve the paraffin or sugar, respectively. Using different sets of sieves, 3D 
scaffold disks with pores in the range of 250-400µm, 125-250µm, and 60-90µm have been 
developed (Figure 1.2). Synthetic polymers have been used extensively in tissue engineering 
approaches using the techniques mentioned as well as many other techniques that have not been 
discussed (i.e. gas foaming, etc.
(38–40)
) to regenerate or support the repair of numerous soft and 
hard tissues
(1)
. These polyester polymer blends are well suited to be processed in this way and 
form high surface area, 3D scaffolds with nanofeatures and good mechanical properties which 
arise from their intrinsic chemical properties and ability to achieve sufficiently high molecular 
weights.  
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Figure 1.2: Interconnected, porous 3D scaffolds made with sugar porogen. Scanning Electron Microscopy (SEM) 
images show poly(L-lactic acid) scaffolds with (A) 125-250 µm pores at 150x, (B) 125-250 µm pores at 500x, (C) 
250-400 µm pores at 150x, and (D) 250-400µm pores at 500x (Scale bar= 100 µm in (A) and (C); Scale bar=10 µm 
in (B) and (D). 
 
1.2.2. Designing hydrogels as tissue engineering scaffolds 
An important class of polymeric scaffolds that are used in tissue engineering is hydrogels. 
Hydrogels, which were first synthetically developed with the advent of contact lenses in the 
1950-60s, are 3D crosslinked networks of polymer that are crosslinked through covalent bonds 
formed via ultraviolet/radical polymerization, click chemistry, thermal gelation, and radical 
polymerization or through physical intramolecular or intermolecular forces such as ionic 
bonding, hydrogen bonding, and hydrophobic interactions
(41–44)
. Unique compared to the 
polymers previously mentioned, hydrogels absorb large amounts of water anywhere from 
hundreds to thousands of times their dry weight, swell without dissolving or losing their structure 
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immediately, and generally have a soft and rubbery appearance in their swollen state. Hydrogels 
have gained attention over the years as scaffolds for tissue engineering application because of 
numerous attractive characteristics. These include their more hydrophilic nature and likeness to 
biological tissues largely comprised of water, their injectability which makes them ideal for 
filling irregularly shaped defects and performing minimally invasive procedures, and their ease 
of modification which allows cells, growth factors, and ligands to be incorporated into the 
precursor hydrogel material. The hydrophilic nature of hydrogels in solution has other 
advantages when compared to traditional polymeric scaffolds in that they provide an aqueous 
environment that can protect cells and encapsulated drugs as well as aid in transport of nutrients 
and wastes to and from cells
(42)
.  Similar to the more hydrophobic polymers previously 
mentioned, hydrogels can be natural, synthetic, or a composite of both naturally occurring and 
synthetic hydrogel materials. Natural hydrogels are made from naturally occurring 
macromolecules found in the body and in nature such as polynucleotides, polypeptides, and 
polysaccharides
(41,45)
. Some well-known natural hydrogels include chitosan, collagen, silk, and 
alginate. These hydrogels have a number of benefits including intrinsic biocompatibility, cell-
mediated degradability, and innate cell binding and interaction motifs. Their disadvantages for 
use in tissue engineering lie in that they have high batch to batch variation and exhibit a limited 
range of mechanical properties, especially after processing for reuse as a biomaterial. Synthetic 
hydrogels, on the other hand, can be made with more precise control in chemistry, structure, and 
function
(45)
. This control allows hydrogels with specific mechanical properties to be fabricated. 
By adjusting the amount of crosslinker or controlling the crosslinking density, hydrogel stiffness 
can be tuned, which is a critical advantage of synthetic hydrogels and makes them a more 
versatile material to create tissue engineering scaffolds. 
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 To perform as a tissue engineering construct, hydrogel scaffolds must meet many of the 
same requirements listed for non-hydrogel scaffolds, mainly (1) they must be biocompatible, (2) 
biodegradable, (3) have high porosity and high surface area, (4) have good mechanical properties 
for the tissue being regenerated, and (5) be cost effective and easily scaled up in production for 
future translation into the clinic. The biggest issue with many hydrogels developed in the 
literature is that they lack biodegradability, have weaker mechanical properties than desired, and 
tend to be non-adhesive to cells. An example of this would be poly(ethylene glycol) (PEG), 
which is widely used as a bulk material to create synthetic hydrogels
(28,43)
. PEG is recognized as 
a chemically and biologically inert material in the field of biomaterials and is often used to 
prevent cell and protein adhesion. When PEG is used in tissue engineering scaffolds, however, it 
is often functionalized by using PEG derivatives with functional groups that can attach various 
adhesion ligands and peptides that help with cell attachment. PEG derivatives are also often used 
as a crosslinker rather than the bulk hydrogel material. While PEG is FDA approved and its use 
has many benefits, the greatest disadvantage is that PEG is not degradable. PEG must be 
manipulated either through copolymerization with degradable polymers such as PGA and PLA 
mentioned earlier, or by adding matrix-metalloproteinase (MMP)-degradable linkages off of the 
PEG backbone. This latter process allows PEG constructs to be broken down by enzymes in vitro 
or in vivo.    
 Two more commonly used polymers for hydrogel fabrication and tissue engineering 
purposes are poly(2-hydroxyethyl methacrylate) (PHEMA) and poly(vinyl alcohol)
(43,46)
. 
PHEMA is characterized by its permeability and hydrophilicity, and with suitable crosslinker, 
PHEMA is used for contact lenses and other ophthalmic applications. Poly(vinyl alcohol) (PVA) 
is produced from poly(vinyl acetate) and its hydrophilicity and solubility can be controlled by 
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adjusting the molecular weight. PVA is fashioned into hydrogels by physically crosslinking most 
commonly with glutaraldehyde. Similar to PEG, PHEMA and PVA are also chemically and 
biologically inert materials that require functionalization and the incorporation of biologically 
active motifs. While bioinertness is often seen as a disadvantage of synthetic hydrogels, it can be 
advantageous when it allows for more control in the type and amount of bioactive ligands that 
are added to the hydrogel which helps regulate cell attachment and behavior. Hydrogel scaffolds 
can also void or minimize the amount of non-specific protein absorption and protein fouling, 
which helps these bioinert materials avoid the foreign body response when implanted in vivo. 
Overall, these hydrogels are more tailorable and can be more precisely designed for specific use. 
The benefits of hydrogel scaffolds in tissue engineering work and the ability to manipulate 
hydrogels as a nanobiomaterial is explored throughout this dissertation by characterizing a novel 
hydrogel material and assessing its biocompatibility and applicability for future tissue 
engineering goals. The monomer class, specific monomer examples, and the monomer selected 
to form a novel hydrogel in this work is introduced in the next section. 
 
1.2.3. Introduction to cyclic ketene acetals, MDO and MTC 
The monomer 2-methylene-1,3-dioxepane (MDO) and its ―second generation‖ molecule, 2-
methylene-1,3,6-trioxocane (MTC) are two of the most basic cyclic or ring monomers from a 
class of polymers known as cyclic ketene acetals (CKAs) (Figure 1.3). First developed in the 
1980s, CKAs are a unique class of polyesters that have not been as heavily explored as 
traditional aliphatic polyesters
(47,48)
. Unlike cyclic esters such as lactide, glycolide, and ɛ-
caprolactone which undergo ring-opening polymerization, CKAs undergo a radical ring-opening 
polymerization (RROP) process, which takes places because of a radical addition process at the 
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vinyl bond
(49,50)
 (Figure 1.4).  This addition is followed by a molecular rearrangement that is 
exclusive to CKAs and leads to the formation of an ester linkage in the polymer backbone. Ester 
linkages are advantageous, especially as it pertains to biomaterials, because through hydrolysis 
they impart degradability to a material. CKAs are an exclusive class of monomers because they 
are the only ones that allow for the synthesis of poly(vinyl-co-ester) materials, and through 
RROP, the synthesis of functionalized polyesters and degradable vinyl polymers. MTC is 
slightly more hydrophilic than MDO due to the addition of an oxygen molecule in its ring 
structure, making it more ideal as a biodegradable material. With a chemical structure nearly 
mimicking that of the previously mentioned polymer PCL, early work alluded to the possible use 
of this polymer as a biomaterial. The low molecular weights achieved during polymerization, 
however, has limited MTC‘s utility for fabrication into robust scaffolding constructs for cell 
testing and subsequent tissue engineering use
(51–53)
. By taking advantage of the MTC monomer 
chemistry, these issues can be overcome by forming a crosslinked hydrogel, which is of infinite 
molecular weight and holds its shape in solution
(54)
. Novel MTC hydrogels are characterized on 
the nano/micro- and macroscale and are tailored to meet the requirements of a hydrogel for tissue 
engineering as described in the previous section. 
 
Figure 1.3: Cyclic ketene acetal (CKA) monomer rings for MDO and MTC. 
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Figure 1.4: Illustration of ring-opening polymerization (ROP) versus radical ring-opening polymerization (RROP). 
(A) ROP of cyclic ester monomers and (B) RROP of cyclic ketene acetal (CKA) monomers. 
 
Part 2: 
1.3. Nanobiomaterials for drug delivery 
In addition tissue engineering, nanobiomaterials are essential to the field of drug delivery and the 
larger field of nanomedicine. As the name suggests, the goal of developing drug delivery systems 
are to serve as effective delivery strategies of therapeutic drugs and agents to specific sites of the 
body, usually in a controlled and/or targeted manner
(55)
. Today, a number of drugs are being 
developed to treat various diseases faced by the general population of the United States such as 
cancer, cardiovascular, inflammatory, and microbial diseases. These drugs are costly, and from 
initiation of development through completion of clinical trials, can cost upwards of $1 billion 
dollars while spanning a decade or longer to produce
(56)
. Along with the high costs and time that 
goes into producing these drugs, many fail to reach the end of clinical trials due to 
biocompatibility or toxicity issues, and fewer make it to the marketplace due to known severe 
side effects
(55,57)
. Some of the current issues with many drug compounds include poor: in vivo 
stability, bioavailability, drug solubility, absorption in the body, and issues with toxicity. An 
additional issue is the difficulty in controlling delivery of the therapeutic agent to a specific site 
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of the body Along with off-target effects, the greatest issue with traditional drugs in pill or 
injection form is that, even when taken as prescribed, dose-related toxicity issues often arise due 
to constant fluctuations in drug concentration in the blood
(58)
. Nanobiomaterials strategies 
developed over the last 40 years have allowed some of the challenges associated with the 
delivery of therapeutics to the body to be overcome. These challenges have been overcome 
particularly by creating materials-based drug delivery systems, to more effectively help cells 
interact with the varying pharmaceutical agents. 
There are a number of advantages that are afforded by combining nanotechnology and 
the field of drug delivery/ nanomedicine
(59,60)
. The greatest benefit of drug delivery, outside of 
allowing more drugs to be viable treatment options due to increased drug solubility and 
bioavailability, is an increase in the efficacy of the many different drug molecules that can be 
delivered using similar drug delivery strategies. Some of the more challenging molecules to 
deliver include DNA, RNA, and some cancer therapy agents; this is difficult due to their 
propensity to become denatured or be cleared by the body, and thus, need adequate protection to 
travel and reach their target sites
(3)
. Through encapsulation, drug delivery vehicles are able to 
form a protective shell that better protects these drugs from harsh conditions such as the highly 
acidic environments of the stomach and lysosomes or enzymes and proteases traveling within the 
bloodstream that breakdown many drugs. Another advantage of nanobiomaterials is the ability to 
deliver drug agents to areas of the body that were once impossible to reach with conventional 
methods such as the blood brain barrier (BBB)
(61,62)
. The BBB is comprised of a dense and tight 
network of vasculature from the central nervous system that acts as a physical barrier to protect 
the brain. Many drugs including antibodies, chemotherapeutic agents, and peptides are inhibited 
from passing through the vessels and capillaries of the BBB. Treating diseases that arise in the 
   
18 
 
brain requires strategies which allow passage through this challenging network. Along with 
helping to maintain doses of drug at a constant therapeutic level for a longer period of time 
within the body, another crucial advantage of drug delivery systems is reducing the instances of 
drug-induced toxicity. Through using these drug delivery methods, more of the drug delivered is 
able to get to the intended site of action and perform its function. Because of this, a lower initial 
dosage of drug can be administered to the patient because a smaller proportion of the drug is lost 
during transit. Having a lower amount of drug released throughout a patient‘s system and away 
from intended site leads to decreased systemic toxicity and diminished side effects. Diminished 
instances of drug-induced toxicity will inevitably lead to fewer deaths due to drug complications 
and milder side effects. Further, reduced instances of complications due to systemic toxicity have 
the potential for improving patient compliance.  
The possibilities for creating drug delivery systems are numerous due to the availability 
of different materials that can be used and nanotechnology techniques which can be employed. 
Generally, nanocarriers are within the size range of 1-1000nm and can be classified into two 
classes: inorganic and organic carriers
(60)
. With a focus on polymeric drug delivery systems, 
different categories of organic carriers will be discussed in the next section. 
 
1.3.1. Types of organic nanocarriers and polymers used for fabrication 
Drug delivery nanocarriers are fabricated with many variables in mind including the choice in 
ideal chemistry or material that should be used and the form or geometry that the carrier should 
take
(1)
. Options for chemistry range from polymers, semiconductors, sol-gels, and self-assembled 
structures made from proteins and DNA. The different geometries or forms that nanocarriers can 
take include various shapes such as nanorods, nanoparticles, and nanoscaffolds. The most 
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common type of nanocarrier is the nanoparticle. Nanoparticles offer many benefits as a drug 
delivery vehicle, many of which are based on the principles of nanotechnology and 
nanomaterials. With a small size and round shape, nanoparticles have a higher payload-to-mass 
ratio, are easy to mass produce, and are injectable, making their delivery minimally invasive. The 
small size of nanoparticles also makes them good at achieving long circulation times within the 
body, by avoiding macrophage uptake, and allows them to circulate relatively quickly
(63)
. 
Nanoparticles can pass through very small blood vessels and capillaries and, as a result, can be 
easily uptaken by target cells through endocytosis. Many subclasses of nanoparticles exist and 
those used most often are discussed here. Included as subclasses of nanoparticles are polymeric 
nanoparticles, micelles, polymeric liposomes (also called polymersomes), and dendrimers.  
Polymeric nanoparticles are most commonly used in drug delivery strategies published 
throughout the literature. Based on the polymer that is used to form these particles, polymeric 
nanoparticles can be designed to tailor the release profile of the encapsulated drugs and thus 
creating a controlled drug delivery system. The drug release profile from these subcellular-sized 
particles is based on the degradation rate of the polymer and can often be adjusted by increasing 
or decreasing the molecular weight of the selected polymer. The synthesis and encapsulation of 
drugs into nanoparticles can be done through different nano-formulation methods such as 
emulsion, diffusion, solvent evaporation, nanoprecipitation, homogenization, sonication, and 
dropwise addition processes among others. These methods of encapsulation can be summarized 
as either a process that (1) entraps the drug into a particle core (nanocapsule) or within a 
polymeric matrix (nanosphere) or (2) a surface adsorption process (Figure 1.5). The most 
commonly used synthetic polymers to fabricate polymeric nanoparticles include poly(lactic-co-
glycolic acid) (PLGA), PLA, PCL, and poly-alkyl-cyanoacrylates
(64)
. These polymers have been 
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used to encapsulate and/or physically adsorb onto the particle surface a wide variety of drugs and 
molecules including anticancer drugs, insulin, antibiotics, anti-inflammatory drugs, and 
hormones among others.  
 
Figure 1.5: Two main classes of polymeric nanoparticles. 
 
Within the class of polymeric nanostructures that are developed for controlled release 
drug delivery applications, there are specific nanoparticle architectures that have been developed 
to take advantage of different chemistries and load drugs with different properties. The three 
most commonly used architectures include micelles, dendrimers, and polymer liposomes 
(polymersomes). Polymeric micelles are nanospheres that are formed by using amphiphilic block 
copolymers that self-assemble when fabricated in a hydrophilic aqueous environment, with the 
hydrophilic portion forming the outside of the particle and the hydrophobic segment forming the 
inner region of the particle
(3,57,59,65,66)
. Generally, the hydrophobic core surrounds and 
encapsulates the added drug and the hydrophilic shell functions to increase both the drug and 
particle solubility. Release of the drug is achieved by disrupting the micelle‘s chains, which can 
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be done through a change in pH, temperature, or another stimulus at the target site. The most 
common amphiphilic di-block copolymers used to fabricate micelles are composed of a 
hydrophobic block of PLGA grafted to a hydrophilic PEG block or another derivative of PEG 
based block copolymer. These micelles that are formed tend to be around 100 nm in diameter. 
This size allows them to escape the clearance mechanisms of the renal and reticulo-endothelial 
systems, circulate throughout the body with greater residence times in vivo, and take advantage 
of the leaky vasculature which is often found in tumors. Micelles have been used extensively in 
research to encapsulate chemotherapeutic drugs with doxorubicin, paclitaxcel, and cisplatin 
being the preeminent examples.  
Similar to micelles, polymersomes are also made of amphiphilic block copolymers, but 
unlike micelles, these block copolymers form a bilayer structure analogous to the phospholipid 
bilayer structure that makes up the membrane of cells in the human body
(67)
. Different from 
micelles, the inner cores of polymersomes form an aqueous hydrophilic core rather than a 
hydrophobic core. Because of this structure, there is greater variability and versatility in the type 
of drugs that can be loaded into this architecture. For instance, a hydrophilic drug can be loaded 
into the hydrophilic core or a hydrophobic drug can be entrapped within the hydrophobic bilayer 
chains. Similar to the previous particle types, polymersomes have been used to encapsulate and 
delivery hydrophobic and hydrophilic drugs, especially chemotherapeutics
(68,69)
.  
Lastly, dendrimers are another major group within the category of polymeric 
nanocarriers. Dendrimers are hyperbranched spherical structures where the branches originate 
from a central core
(59)
. They are attractive for use in drug delivery because their structure 
provides the ability to hold drugs in the core microenvironment formed by the surrounding 
branches and allows for packing within the spaces of the multiple branches. Depending on the 
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dendrimer chemistry, the dendrimer surface can be highly functionalized, with end groups 
dictating the macroscopic properties of the dendrimer
(70)
. Similar to the particle types previously 
mentioned, dendrimers have been used to deliver varying drugs such as common anticancer 
therapeutics named earlier. Polyamidoamine (PAMAM), a classically used dendrimer polymer, 
has been employed in drug delivery to conjugate doxorubicin through amide and hydrazone 
linkages for photochemical release of the drug inside cancer cells and has also been used as a 
non-viral vector for DNA gene delivery
(71,72)
. While the hyperbranched structure of dendrimers 
may be desirable and allow for a high degree of functionalization, drugs loaded into dendrimers 
are often released quickly and fail to achieve long-term release due to the lack of encapsulation 
of the drug by dendrimers
(73,74)
. Choosing an ideal nanocarrier or drug delivery system relies on 
thorough knowledge of the physical and chemical properties of the drug being loaded as well as 
the encapsulation and release kinetics of the different particle systems mentioned. This allows 
better decisions to be made on the most advantageous particle system for efficient delivery of 
different therapeutic agents.  
 
1.3.2. Hydrogels for drug delivery 
Along with the polymeric nanoparticles that have been developed as drug delivery systems, 
hydrogels, previously mentioned for their utility in tissue engineering, have also been utilized in 
the drug delivery space to create controlled drug delivery systems
(75,76)
. Hydrogels are 
crosslinked networks of homopolymers or copolymers that are formed into three-dimensional 
structures and are highly biocompatible due to the high water content of these systems
(77–79)
. The 
crosslinks within these constructs help provide the overall structure and physical and chemical 
integrity to hydrogels. When placed in an aqueous environment, hydrogels exhibit a swelling 
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behavior that is not only dependent on the chemical structure and degree of crosslinking, but can 
also be dependent on the environmental conditions such as temperature, electromagnetic field, 
pH, and presence of ions.
(80)
. The characteristic physical properties of hydrogels make them 
particularly useful for drug delivery use as they are generally highly porous and form an internal 
mesh, which can be tuned by adjusting the crosslink density and changing the swelling 
dynamics. This mesh network and porosity allows for drugs to be loaded directly into the gel 
matrix or into polymeric nanoparticles that are subsequently loaded into the gel matrix. Drug is 
then released at a diffusion rate that is also dependent on the hydrogel swelling rate and 
degradation rate, which must tested and tuned depending on the desired release behavior. Similar 
to the polymeric nanoparticles previously described, many different therapeutic molecules have 
been delivered using hydrogels including small molecule hydrophilic drugs and more fragile 
biomacromolecules such as peptides, protein, and DNA, which are often harmed by the 
degradation byproducts of polymeric nanoparticles. Many hydrogels fail to meet the ability to 
release small molecule hydrophobic drugs in a controlled manner, which highlights a need for 
hydrogels that meet this criterion
(81)
. Nevertheless, encapsulating these hydrophilic drug agents 
has been done by fabricating hydrogels into nanoparticles, microparticles, coatings, thin films, 
and standalone drug reservoirs. A number of synthetic polymers have been explored for hydrogel 
drug delivery purposes including poly(hydroxyethyl methacrylate) (HEMA), poly (N-
isopropylacrylamide) (PNIPAAM), PVA, PEG block copolymers with PLGA, PLA and other 
hydrophobic segments, and poloxamer/ Pluronic based block copolymers comprised of 
poly(ethylene oxide) and poly(propylene oxide)
(76–78)
. There are a number of design criteria 
when developing an ideal drug formulation. Taking into account transport properties (crosslink 
density, polymer-drug interactions, hydrogel degradation rate), physical properties (component 
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concentrations and molecular weights, temperature, pH, ionic strength), and biological properties 
(component and construct biocompatibility) is crucial in designing the most efficient hydrogel 
system
(75)
. This topic is further explored within this dissertation.  
 
1.3.3. Targeted drug delivery 
In designing drug delivery system using nanobiomaterials strategies, one of the greatest 
considerations that must be made is whether the system will be a passive targeting system or an 
active targeting system
(64,82–87)
. Passive targeting refers to drug delivery approaches that take 
advantage of natural properties of the developed system and phenomena within the body to help 
nanoparticles accumulate at an intended site of action. Passive targeting simply refers to a 
nontargeted system that relies on the particle size and surface charge to aid in transport through 
the body. By achieving long term circulation in the body based on these parameters, particles can 
increase uptake into tumors or disease areas simply due to concentration gradients. Specific to 
solid tumors, particles can achieve high accumulation in the tumor mass due to the enhanced 
permeability and retention (EPR), which happens when a rapidly growing tumor forms a leaky 
vasculature network and develops inefficient lymphatic drainage system
(87,88)
. While 
nanotechnology is beneficial in this scenario and is more effective than systemic delivery of the 
free drug, it is not the best delivery approach. 
Active targeting, on the other hand, takes passive or nontargeting drug delivery systems 
and chemically attaches or physically adsorbs a targeting agent to the surface of the 
nanocarrier
(3,59,89)
. The targeting agent must have high affinity and be specific to a tissue or cell 
ligand, helping to home particles to a site of action. This active targeting strategy increases the 
efficacy of the nanoparticle itself and, in turn, that of the loaded drug. Active targeting is 
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particularly useful in treating different cancers and similar diseases where a ligand is 
overexpressed and/or not present on healthy cells
(86)
. There are a couple factors that contribute to 
how well an actively targeted approach works including the conjugated ligand‘s density, the size 
of the nanoparticles, and the charge on the nanoparticle surface. The greatest consideration, 
however, is the choice of targeting ligand presented on the particle surface. A recent study has 
shown that many particles fail to reach their target sites, with only 0.7% of administered particles 
reaching their target tumor cells, due to multiple factors, including poor ligand selection, affinity, 
and particle internalization
(90)
. The choice of ligand includes small molecules such as vitamins, 
sugars, and aptamers (nucleic acids), but most commonly are proteins, antibodies, or 
peptides
(83,86,89)
. Proteins have been considered in creating actively targeted drug delivery 
systems because of their great affinity for various targeting receptors
(83)
. Overall the use of whole 
proteins is not ideal, however, due to their large size and the complexity involved in attaching 
them to the surface of nanocarriers. Monoclonal antibodies have also been conjugated to the 
surface of nanoparticles and take advantage of specific antibody-antigen interactions to help treat 
a disease. The mechanism of action of these monoclonal antibodies conjugated to a particle 
surface include interfering with another antibody- antigen interaction, or binding itself to the 
antigen on the cell surface to suppress protein expression. Antibodies have been used widely 
within research over the past couple decades. The most well-known antibody targeting 
treatments would be for the targeting of epidermal growth factor receptor (EGFR/HER2). Since 
EGFR is involved in cell proliferation, antibodies are often used to block EGFR activation using 
an antibody-interference strategy. Other strategies, such as the use of the drug trastuzumab, 
which is a monoclonal antibody, actively work to kill HER2 overexpressing (HER2+) cancer 
cells. While the use of antibodies allow for high specificity in targeting, their use also carries 
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notable disadvantages. The disadvantages of using antibodies include the exorbitant cost 
associated with their development, modification, and research which leads to expensive drug 
production, their propensity to trigger immune responses in humans, and their poor ability to 
penetrate tumors due to the large size and bulkiness of the antibody-particle conjugate.  
Similar to antibodies, peptide sequences take advantage of ligand-receptors. Peptides are 
short 10-15 amino acid sequences (no longer than 50 amino acids) and are essentially fragments 
of antibodies and proteins. Peptides can be screened using phage display analysis to create 
libraries of peptide sequences that have high affinity to specific cell types. Through phase 
display technology, a number of peptide sequences have been identified such as the arginine-
glycine-aspartic acid (RGD) sequence that has been recognized as a cell adhesion peptide 
because of its affinity to integrins found on many cell surfaces
(91–93)
. Targeting peptides have 
been used in research to treat diseases ranging from immune system diseases to multiple cancer 
types including glioma, prostate, lung, ovarian, and breast cancers
(83,94,95)
. The use of peptides in 
targeting strategies is advantageous over the use other targeting moieties because they have a 
smaller size, a simple 3D structure which leads to improved stability in vivo, and are cheaper and 
easier to synthesize and conjugate to nanocarriers
(86)
. Targeting peptides and their efficacy is 
explored in this dissertation, specifically for improving HER2+ breast cancer targeting. A 
recently identified HER2+ peptide is incorporated into a nanoparticle drug delivery system 
exploring modifications that can be made to both the peptide and the nanoparticle to increase 
nanoparticle binding and internalization into HER2+ breast cancer cells.   
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1.3.4. Motivation for HER2+ breast cancer targeting 
According to the National Cancer Institute at the National Institute of Health, since 2006 there 
have been more than 200,000 new cases each year of breast cancer in women with more than 
41,760 estimated deaths alone in 2019 
(96,97)
. Breast cancer is the most commonly diagnosed 
cancer in women and currently the third most common cause of cancer deaths in women. Within 
all the different breast cancer subtypes, 15-20% of breast cancers overexpress the human 
epidermal growth factor receptor (HER)-2. HER2+ breast cancers tend to have very poor 
outcomes for patients due to the aggressive nature of the cancer, their propensity to metastasize, 
and resistance to endocrine therapy owing to decreased expression of estrogen receptors
(96,98,99)
. 
The push for early breast cancer screening and the introduction of the monoclonal antibody 
trastuzumab when used in conjunction with chemotherapy has improved the prognosis of 
patients with HER2+ breast cancer slightly. Nevertheless, a large population of HER2+ patients 
fail to respond to trastuzumab and other treatments completely, and a significant fraction of 
patients that initially respond to treatment tend to relapse within 1-5 years of initial treatment
(99)
. 
The recurrence, progression, and eventual metastasis of the disease often lead to patient death. 
Treatment approaches to breast cancer depend on the specific disease type, staging, and 
progression. Treatment may include a combination of surgery, radiotherapy, and systemic doses 
of chemotherapy, endocrine therapy, and/ or biologic therapy
(100)
. Despite the great deal of 
research that has gone into treatment and therapies for breast cancer, these ―gold standard‖ 
approaches have not changed significantly in a number of decades. These approaches also have 
significant disadvantages in that they are invasive and can become quite extensive if lymph 
nodes are involved, with regards to surgery, and are systemic, leading to severe side effects in 
the case of chemotherapy, radiation, and other therapy options. Instead of systemic treatment, 
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drug delivery techniques can be employed to develop focused and more efficacious therapeutic 
options, which would ultimately help decrease the number of HER2+ breast cancer recurrences 
and deaths. Improving the efficacy and reducing the invasive and systemic nature of current 
treatments is an overarching goal of cancer drug delivery and can be achieved by combining and 
building on the nanotechnology and drug delivery strategies mentioned here. 
 
1.4. Dissertation Overview 
This dissertation is divided into two main parts. Part 1 (Chapter 2) focuses on tissue engineering 
and how properties can influence a material‘s suitability as a tissue engineering scaffold or 
biomaterial. Part 2 (Chapters 3 and 4) focuses on two different drug delivery strategies and how 
varied drug delivery approaches may be to achieve goals such as controlled release or active 
targeting. Chapter 2 presents a novel hydrogel biomaterial made by crosslinking the CKA 
monomer MTC, previously introduced, with poly(ethylene glycol) diacrylate (PEGDA). As 
discussed in the introduction, biomaterials must be designed with spatial and temporal 
considerations in mind. Polymeric and hydrogel scaffolds have been developed that either lack 
the mechanical properties needed for specific tissue regeneration, degradability over time, or 
processability that are desired to make an improved tissue engineering scaffold. The hydrogel 
scaffold developed here addresses these issues specifically and characterizes this novel material 
for biomaterials use generally. Multiple hydrogel compositions of MTC and PEGDA crosslinker 
are fabricated by changing the crosslinker concentration and length to determine how this 
chemistry and variations in the crosslinker affect properties such as wettability, degradation, 
stiffness, and structural changes on the nano/micro and macroscales. The processability of this 
hydrogel fabricated from a hydrophobic bulk material is also explored to determine the 
   
29 
 
biocompatibility of the hydrogel compositions and how this relates to the hydrogel and scaffold 
requirements presented in the introduction and overcomes the hydrogel disadvantages discussed. 
Chapter 3 extends the utility of this novel hydrogel material to determine how the release of 
drugs with different properties (i.e. small molecule hydrophobic, small molecular hydrophilic, 
and proteins) are released from this hydrogel material. The issues with tuning and tailoring 
hydrogel systems for controlled drug release as well as the lack of versatility of drug loading in 
traditional hydrogel systems that are only suitable for hydrophilic drugs are addressed. The 
injectability of the MTC material and ability to crosslink in situ is also assessed. The crosslinker 
lengths and concentrations are varied more drastically to determine if release trends change with 
greater changes in the crosslinker concentration. Chapter 4 shifts to a nanoparticle targeting 
strategy using an identified HER2 targeting peptide followed by combination targeting and 
internalizing peptide sequences that pivoted from the initial targeting sequence. Two different 
PEG spacer chemistries are also tested and compared to evaluate if increased peptide 
presentation leads to greater targeting and/or uptake by HER2+ breast cancer cells, combining 
some of the nanotechnology and biomaterials strategies previously mentioned. Through these 
approaches, HER2+ targeting is tackled to improve the selectivity and internalization ability of 
drug-loaded polymeric nanoparticles to overcome the systemic issues (nonselectivity and harsh 
side effects) of current chemotherapy administration. Finally, Chapter 5 provides insight for 
future work and specific ways in which the MTC hydrogels can be applied to for both tissue 
engineering and drug delivery application, and how the HER2+ targeting nanoparticles will be 
robustly tested in a clinically relevant transgenic in vivo mouse model. 
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Chapter 2. Hydrogels with Unique Swelling Properties as a Biomaterial for Tissue 
Engineering Application 
 
 
Prepared for publication in Chemistry of Materials with co-authors: Navarro R*, Zhang Z, 
Xiang Y, Awada M, Adler N, and Ma PX., ―Hydrophobic hydrogels with reverse swelling and 
tunable properties as a biomaterial for tissue engineering application.‖ *Both authors contributed 
equally to this work.  
 
2.1. Introduction 
Hydrogels have been widely used in industry and by biomaterial scientists since the late 1950s 
for many applications, including as tissue engineering substrates to regenerate tissues and 
organs
(42,46,101–110)
. Made from natural and/or synthetic polymers, hydrogels are hydrophilic 
polymer networks that have the ability to absorb up to thousands of times their dry weight when 
placed in water. To be suitable for tissue engineering applications and help cells perform their 
function, hydrogel scaffolds should meet a number of requirements, including (1) being 
biocompatible, (2) being biodegradable, (3) having high surface area, and (4) having mechanical 
properties that are compatible with the tissue that is being regenerated
(27,28)
. A number of 
hydrogels developed fail to meet one or more of these requirements, and especially lack 
biodegradability and/or have weak mechanical properties as exemplified in many of the typical 
materials used for hydrogel formation such as polyethylene glycol (PEG) and polyvinyl alcohol 
(PVA). The best scaffolds for tissue engineering also have high porosity and interconnectivity 
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between the pores
(28)
. Achieving this in hydrogels is often done through methods such as 
photolithography, freeze drying, and gas foaming, which are challenging and costly. Advancing 
the types of scaffolds available, specifically by improving hydrogels to meet the listed 
requirements above by developing novel materials with different properties, continues to be a 
goal of tissue engineering.    
2-methylene-1,3,6-trioxocane (MTC) is a ring monomer from a class of polyesters known 
as cyclic ketene acetals (CKAs). CKAs are unique because they undergo a molecular 
rearrangement upon radical ring-opening polymerization (RROP)
(47–50,111,112)
. RROP leads to the 
formation of a hydrolysable ester linkage in the hydrophobic polymer backbone that imparts 
degradability into the structure, overcoming the lack of biodegradability found in many hydrogel 
systems. Furthermore, this extraordinary chemistry lends itself to crosslinking through the 
radical produced and a diacrylate crosslinking molecule. The greatest hurdle using MTC to 
develop tissue engineering scaffolds has been polymerizing to high molecular weights, which 
has been previously attempted through traditional radical polymerization schemes in the 
presence of solvent
(111,113)
. The loosely crosslinked MTC gels that polymerized in these instances 
resembled weak elastomers instead of intact hydrogels. These gels overall exhibited poor 
mechanics, low degrees of swelling, and relied on added enzymatic degradation. Because MTC 
is difficult to polymerize to high molecular weights, a necessity for robust scaffold fabrication, 
the issue of low molecular weight is overcome in this work by crosslinking MTC into a hydrogel 
with high (infinite) molecular weight. In this way, the MTC chemistry, degradability, and 
hydrogel properties could all be taken advantage of. 
Through chemical (covalent) crosslinking, a robust hydrogel can be formed. PEG and its 
derivatives such as poly(ethylene glycol) diacrylate (PEGDA) have been used not only to form 
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bulk hydrogel materials, but also as a crosslinker. PEGDA is beneficial for use as a crosslinker 
due to its neutral charge, hydrophilicity, good biocompatibility, resistance to protein absorption, 
and functionality
(76,114–118)
. Taking advantage of these strengths and the chemical structure of 
MTC previously mentioned, it was hypothesized that MTC could be covalently crosslinked with 
PEGDA to form a new, degradable, and tunable highly crosslinked hydrogel material. It was also 
hypothesized that a reverse hydrogel system such as this one, composed from a hydrophobic 
bulk material and a hydrophilic crosslinker, would display unique properties, especially as it 
pertains to the swelling behavior. 
In this work, a series of MTC hydrogels were developed by varying the crosslinker length 
and molar concentrations to determine the different properties of PEGDA crosslinked MTC 
hydrogels and examine how MTC gels can change from non-swelling to swelling. It was found 
in this MTC hydrogel system that an increase in swelling is observed as the crosslinking density 
is increased, where generally a decrease in swelling is seen as the number of crosslinked points 
are increased within traditional hydrogels
(75,119)
. Finally, a notable characteristic of the MTC 
monomer is that it exists in a liquid state at room temperature that is miscible with its PEGDA 
crosslinker and does not need added water or solvent for crosslinking, which allowed for scaffold 
processing that is generally not possible with traditional aqueous hydrogel solutions. Capitalizing 
on this advantage, a one-pot reaction is used to fabricate hydrogels with an interconnected and 
porous morphology. The hydrogels were fabricated for the first time using a facile previously 
developed sugar porogen method
(34,35,37)
. Combining all of the advantages of the MTC monomer 
and desired hydrogel properties, MTC gel/hydrogel compositions were characterized and, based 
on ideal mechanics and swelling behavior, the biocompatibility of this novel hydrogel material as 
a tissue engineering scaffold was assessed.   
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2.2. Results and Discussion 
2.2.1. Effect of changing MTC concentration and varying crosslinker percent and length on 
structure of dry and swelled crosslinked MTC 
Through the modified MTC synthesis reactions described in the methods section as well as 
depicted in the reaction scheme, a greater yield of MTC monomer was achieved with an overall 
yield of 25-30% compared to the 10% yield previously achieved by Undin et al., which may be 
due to higher vacuum during the distillation steps and preventing the monomer from degrading 
during heating
(51)
 (Figure 2.1a). Using this ultrapure monomer (purity ~99.5%), a series of gels 
and hydrogels were fabricated according to the radical ring opening polymerization (RROP) and 
crosslinking schemes illustrated (Figure 2.1b and 2.1c). Through the MTC monomer molecular 
rearrangement and subsequent reaction through the C=C bond in poly(ethylene glycol) diacrylate 
(PEGDA), a crosslinked network is quickly formed with the addition of DMPA UV initiator and 
365 nm wavelength UV light source. Unique to cyclic ketene acetals, this molecular 
rearrangement is significant because it leads to the formation of a desired ester linkage in the 
polymer backbone and degradability to the forming polymer. Degradability is a beneficial 
feature of tissue engineering scaffolds as scaffolds degrade over a specific time range in order to 
allow cells to remodel their environment, form new tissue, and deposit extracellular 
matrix
(120,121)
. 
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Figure 2.1: 2-methylene trioxocane (MTC) reaction steps, ring opening, and UV crosslinking schemes. (A) 
Reaction 1 forming MTC intermediate chloromethyl trioxocane and Reaction 2 forming MTC cyclic monomer. (B) 
Radical ring-opening polymerization forming linear chain with primary radical. (C) Gel/hydrogel network formed 
through crosslinking of MTC and PEGDA. 
 
First, a notable change in the overall diameter of gel/hydrogel samples is observed in the 
sample disks following initial gelation under UV light and after allowing the samples to swell for 
just 24 hours in water. Throughout this paper, gels will refer to crosslinked samples that do not 
swell significantly (less than 100%), while hydrogels will refer to crosslinked samples that have 
a percent swelling of 100 or greater. Differences in the degree of swelling are seen as the mole 
ratios of MTC monomer and crosslinker, which is calculated with respect to the moles of MTC 
monomer, and the crosslinker length are varied. An example can be seen for the changes that 
occur in the diameter of MTC disks for two different mole percents of crosslinker (0.25% and 
1.0%) as well as with varying the crosslinker length (Figure 2.2). This swelling phenomenon 
supports the notion that this hydrogel system may show unique swelling properties and will be 
more robustly examined and quantified in the next section. 
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Figure 2.2: Effect of changing crosslinker concentration (mole percent) and length on gel/hydrogel swelling. 
 
Along with this observed gross macroscopic change, changes on the microscopic level 
are also observed for the gel/hydrogels compositions. Using scanning electron microscopy, 
cross-sections of MTC gels/hydrogels were prepared and imaged after gelation as well as after 
submersion in water (swelling) and subsequent lyophilization. While the images immediately 
after crosslinking tend to show a typically smooth surface or rippled appearance due to the tight, 
enclosed pores, the more classical hydrogel mesh can be seen after submerging the gel/hydrogel 
disks in water for 3 days (Figure 2.3). There is also an interconnected porous morphology that 
forms through the gels/hydrogels, with pores that range from 1-10 µm in size. MTC samples 
crosslinked with the shortest PEGDA crosslinker (575 Da) show the same morphology before 
and after swelling, as seen in Appendix A. An increase in mesh size can be seen as the 
crosslinker mole percent increases from 0.25% to 2.5% (relative to moles of MTC monomer) and 
as the PEGDA length is increased from 2 kDa to 8 kDa. Increasing the PEGDA molecular 
weight from 575 Da to 8 kDa increases the hydrophilicity of the MTC gels/hydrogels. Likewise, 
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increasing PEGDA mole ratio also shows an increase in gels/hydrogels hydrophilicity. With an 
increase in hydrophilicity, these hydrogels are able to draw more water throughout the 
crosslinked MTC network and swell. Apparent in the SEM images and found in some hydrogels 
is the fibrous architecture that is observed upon swelling across the different MTC gel/hydrogel 
compositions, especially with the 1.0% and 2.5% MTC gels/hydrogels. A nanofibrous 
architecture has been found to mimic the extracellular matrix and help promote increased cell 
attachment and differentiation on synthetic polymer scaffolds
(37,122–124)
. 
 
Figure 2.3: Effect of varying percents of MTC and PEGDA crosslinker as well as PEGDA length on structure of 
MTC samples after swelling. All samples were visualized using scanning electron microscopy after submerging 
sample in water for 3 days and subsequently lyophilizing before imaging. (Scale bar= 10 µm).   
 
2.2.2. Effect of varying MTC concentration and crosslinker percent and length on swelling and 
degradation (mass loss) behavior of MTC gel/hydrogel samples 
The swelling and degradation behaviors of the MTC gels/hydrogels were assessed and quantified 
as the crosslinker length and percent were changed. The behavior of the different samples was 
examined over a period of up to 11 weeks (Figure 2.4). From the graphs produced, MTC 
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hydrogel samples with 2.5% percent PEGDA have the greatest swelling percent overall 
compared to gel/hydrogel samples fabricated with 1.0% and 0.25% PEGDA. MTC hydrogels 
prepared with 8 kDa 2.5% PEGDA swelled nearly 800% times their original dry mass and could 
be appropriately described as hydrogels. Similarly, MTC samples with 4 kDa 2.5%, 2 kDa 2.5%, 
8 kDa 1.0%, and 4 kDa 1.0% achieved swelling percents between 100-500%, showing 
behavioral characteristics consistent with these samples‘ classification as hydrogels. The 
remaining samples, however, fail to show substantial swelling (575 Da 2.5%, 2 kDa 1.0%, 575 
Da 1.0% and all 0.25%) as the hydrophobic nature of sample supersedes the hydrophilic 
components and can more fittingly be described as gels as they do not absorb much water. 
 
Figure 2.4: Effect of varying MTC concentration and crosslinker percent and length on swelling and degradation 
(mass loss) behaviors of MTC gel/hydrogel samples. Swelling (A-C) and degradation (D-F) studies were performed 
for up to 10 weeks in pH 7.4 PBS at 37 °C for the varying MTC gel/hydrogel samples. Data are presented as mean ± 
standard deviation (n=3). 
 
The percent of mass loss over time is shown for the crosslinked gel/hydrogel disks as 
well (Figure 2.4). MTC samples crosslinked with variable percents of 575 Da PEGDA always 
have the slowest rate of mass loss when compared to samples with the same percent of 
crosslinker. A minor decrease in the ratio of MTC to crosslinker leads to gels/hydrogels which 
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show an increase in rate of mass loss over time. The only true exception to this trend would be 
for the MTC samples crosslinked with 8 kDa 2.5% PEGDA, where the overall mass of PEGDA 
at 2.5 mole percent is greater than the mass of MTC. As mentioned in the introduction, PEGDA 
is not degradable and, because of this, the samples maintain their mass comparatively.  
Along with the tunability of this hydrogel system, it can be concluded from the swelling 
and mass loss behavior that the hydrophobicity and hydrophilicity affect the degree of swelling 
and the rate at which mass decreases for the MTC gels/hydrogels. This is truly distinctive in the 
case of swelling with respect to the crosslinker percent because generally as the percent of 
crosslinker is increased in hydrogel systems, there is a decrease in swelling and mesh 
size
(75,119,125)
. Instead, there is a consistent increase in swelling as the percent of crosslinker is 
increased throughout this work. This suggests that the more hydrophilic a sample is, either 
because of higher concentration (mole percent) of PEGDA or, more traditionally, higher PEGDA 
molecular weight, the more a sample swells or the faster a sample degrades as more water is 
brought into the MTC sample. This is despite more crosslinking within the sample, which 
usually restricts swelling. These two effects were further studied with additional data to reflect 
each condition separately. First, the effect of changing the crosslinker length was isolated by 
keeping the mass of both MTC and the mass of crosslinker constant amongst the different 
samples and observing the swelling behavior over a one-week period (Figure 2.5a). The effect 
of crosslinker length is clear as the samples rapidly swell as crosslinker molecular weight 
increases. Similar to the complete swelling tests previously discussed, samples with fixed mole 
percents of crosslinker relative to moles of MTC monomer were prepared at 2x (0.5% to 1.0%) 
and 5x (0.5% to 2.5%) concentrations (Figure 2.5b, Figure A.4). In line with the previous 
swelling test and gross image of the samples, an increase in swelling is seen as the hydrophilic 
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PEGDA crosslinker ratio is increased in the gel/hydrogel samples. This hydrophilicity-
hydrophobicity balance is able to overcome the physical limitation placed on water absorption 
that traditional hydrogels are restricted by with regards to swelling behavior. For hydrogels, this 
is truly unique and has yet to be described in previous hydrogel systems.  
 
Figure 2.5: MTC gel/hydrogel swelling with fixed MTC and PEGDA masses and fixed mole percents to determine 
hydrophilic effect on swelling behavior. (A.) Fixing the mass at 0.9 g MTC and 0.1 g PEGDA crosslinker, samples 
were prepared and left to swell over 7 days in PBS pH 7.4. (B.) Fixing the mole percents of 4 kDa PEGDA 
crosslinker with respect to moles of MTC monomer and measuring the degree of swelling over 7 days in PBS pH 
7.4. All values reported as mean ± SD (n=3). Error bars are smaller than size of markers on graph.   
 
2.2.3. Correlating relative degree of crosslinking as MTC and crosslinker ratio are varied and 
crosslinker length increases using differential scanning calorimetery (DSC) 
Through the experiments performed, the change in glass transition temperature (Tg) of the 
gels/hydrogels was determined using the second cycle heating curves and inflection point 
analysis. For the first time ever, the glass transition temperature of MTC polymerized by itself 
was also found and used as a reference for the crosslinked samples. Through a standard bulk 
polymerization reaction using Cumene hydroperoxide as an initiator, polymerized MTC 
achieved a molecular weight of 11,534 g/mol. Through DSC, the Tg was found to be -66.81 °C. 
This Tg is comparable to that of PCL, which MTC mimics in structure. The backbone of MTC, 
however, exhibits added flexibility with the addition of oxygen throughout the structure making 
the Tg of MTC lower than that of PCL. An examination of how changing the crosslinker length 
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and ratio within the MTC hydrogels was done for the range of crosslinker lengths and percents 
previously mentioned. From the data summarized in Figure 2.6a-d, it is generally seen that the 
longer the crosslinker (4 kDa and 8 kDa PEGDA), the lower the Tg, and when the crosslinker 
length is shorter (575 Da and 2 kDa), the Tg is higher. The small range in the amount of 
crosslinker used in this work does not show a clear trend according to the DSC data collected. 
However, a slight positive slope in the FTIR graph suggests that more PEGDA crosslinker is 
incorporated into the gel/hydrogels samples (Figure 2.6e). This data was found by measuring the 
area under the curve of the 3000 cm
-1
 (-CH2
 
stretching from PEGDA backbone) and 1750 cm
-1
 
(C=O ester stretch from MTC) peaks to form a ratio of [PEGDA]/[MTC]. 
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Figure 2.6: Determining glass transition temperature (Tg) of polymerized MTC and MTC gel/hydrogel 
compositions to evaluate differences upon varying MTC-PEGDA concentration and PEGDA molecular weight 
(length). (A) and (C) Tg
 
of 575 Da and 2 kDa PEGDA crosslinked MTC samples; (B) and (D) Tg of 4 kDa and 8 
kDa crosslinked MTC samples; (E) FTIR analysis showing the ratio of A3000 cm-
1
/A1730 cm
-1
 or the relative amount of 
[PEGDA]/[MTC] incorporated into samples. The Tg onset and Tg,inflection were found for the  samples. 
 
The literature has previously reported that the Tg is a function of the degree of 
crosslinking and that the higher the Tg, the greater the degree of crosslinking
(126–128)
. As the 
number of crosslinks is increased overall, the mobility of the polymerized gel/hydrogel becomes 
restricted and the temperature to relieve this chain restriction increases. With this information, a 
smaller crosslinker length leads to a higher degree of crosslinking within the fabricated MTC 
gels. On the other hand, a longer PEGDA crosslinker leads to a lower degree of crosslinking 
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within the MTC samples. This information concurs with the swelling behavior previously 
discussed. It can also justify, along with the hydrophobicity and hydrophilicity of the 
gels/hydrogels, why a larger mesh or pore size is seen as the crosslinker length is increased, as 
previously it was determined that as the degree of crosslinking increases, the amount of water 
penetration and an increase in mesh size and swelling is hindered
(129)
. The relative degree of 
crosslinking as determined from the Tg is also useful in predicting a trend in mechanical 
properties presented in the next section.    
 
2.2.4. Effect of varying MTC concentration and crosslinker percent and length on elastic 
modulus (G’) of MTC gel/hydrogel samples immediately after gelation and after swelling 
and the correlation to degree of crosslinking 
It was investigated how varying the ratio of MTC monomer to crosslinker percent and changing 
the crosslinker length changes the elastic modulus of the crosslinked MTC gels/hydrogels. The 
elastic modulus is a critical parameter in characterizing the crosslinked MTC samples and 
dictates future applications, especially as it pertains to use as a biomaterial for tissue engineering. 
The elastic moduli were measured immediately after crosslinking and following 3 days of 
submersion in water (swollen). Using a rheometer, G‘ is summarized as crosslinker percent and 
length are varied at a static frequency and is also shown according to the 3 different crosslinker 
percents of samples across a frequency sweep (Figures 2.7 and 2.8). All of the gels/hydrogels 
exhibited strong elastic solid like behavior and did not show overwhelming viscoelastic behavior 
with relatively low G‘‘ behavior (not shown). When samples were measured immediately after 
gelation in their initial dry state, it was found that increases in the PEGDA crosslinker 
concentration and length both led to pronounced increases in the elastic modulus. A greater 
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difference in the modulus values is also seen among each group of fixed crosslinker percents, 
although fairly constant modulus values were measured as frequency is increased. From the 
permutations of gels/hydrogels fabricated by varying the PEGDA mole percent and length, 
different moduli were measured in the range of approximately 100 kPa for the more robust 1.0% 
and 2.5% crosslinked samples and in the range of 1.5 kPa for the more lightly crosslinked 
samples. As mentioned, an increase in G‘ is seen for the samples measured in the initial dry state 
as crosslinker length is increased. This decreased ability to resist deformation and therefore 
greater elasticity (G‘), can be explained through properties of Rubber Elasticity Theory(119). An 
increase in the modulus as crosslinker concentration and length are increased is not only 
attributable to an increase chain entanglements and viscosity as more and longer crosslinker is 
incorporated in a dry, packed state, but can also be related to the degree of crosslinking
(130). G‘ 
and crosslinking density have been correlated through the equation
(131)
: 
         
where   is the number of crosslink sites per unit volume, R is the universal gas constant, and T is 
the temperature. After standing in water for a few days, the samples have similar elastic moduli 
values, especially as crosslinker length is increased, and have a narrow range in the measured 
moduli. The most obvious change in moduli between the initial (dry) and wet samples can be 
observed in those crosslinked with 8 kDa PEGDA, where a longer crosslinker, and greater 
uptake of water as seen in the swelling behavior, can be attributed to a decrease in elastic 
modulus as water acts as a plasticizer in this instance
(131)
. This reversal in modulus values can be 
seen across all 3 crosslinker percents, though on a more subtle scale for the lower crosslinker 
molecular weights.   
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Figure 2.7: Effect of varying crosslinker length and percent on elastic modulus (G') of MTC gels/hydrogels before 
and after swelling at a fixed frequency. (A) Initial G‘ (dry) with respect to percent of crosslinker, (B) Initial G‘ (dry) 
with respect to crosslinker length, (C) G‘ after swelling for 3 days with respect to percent of crosslinker, and (D) G‘ 
after swelling for 3 days with respect to crosslinker length. 
 
 
Figure 2.8: Effect of varying crosslink percent and length on elastic modulus (G‘) of MTC gels/hydrogels before 
and after swelling over a frequency sweep. G‘ elastic modulus values were measured for the samples immediately 
after fabrication for (A) 2.5 mole percent crosslinker, (B) 1.0 mole percent crosslinker, and (C) 0.25 mole percent 
crosslinker. G‘ elastic modulus  values after swelling for 3 days for (D) 2.5 mole percent crosslinker, (E) 1.0 mole 
percent crosslinker, and (F) 0.25 mole percent crosslinker. The modulus values are generally consistent across the 
measured frequencies of 0.1 to 100 rad/s. 
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2.2.5. In vitro testing of ADSCs and DPSCs on gels/hydrogels to determine cell survival, 
proliferation, and infiltration into hydrogel scaffolds 
Following all of the materials characterization, biocompatibility testing was done to assess the 
suitability of MTC gels/hydrogels as a biomaterial for tissue engineering use. The first 
assessment was done through a cell proliferation assay of all the gels/hydrogels. Using the 
samples with good cell proliferation, SEM imaging and a Live/Dead cell assay and imaging were 
performed next. While a porous mesh with 1-10 µm pores is produced after the gels/hydrogels 
are submerged in water, this network itself does not produce an adequately sized, interconnected 
network for cells to thrive long-term. To improve these conditions and taking advantage of the 
anomalous lack of solvent needed for MTC gel/hydrogel crosslinking, an interconnected, porous 
network was introduced into the material using a sugar bead template method previously 
described. This is the first time this facile sugar porogen method was used to form porous 
hydrogels. Using this method is only possible due to the absence of water or another solvent in 
the gel/hydrogel crosslinking process. These porous MTC gels/hydrogels were used for the 
remaining tissue engineering testing. In vitro testing was done by seeding adipose-derived stem 
cells (ADSCs) and dental pulp stem cells (DPSCs) onto the scaffolds to evaluate the utility for 
more than one stem cell source. Proliferation assays were performed over one week to determine 
which MTC-PEGDA compositions promoted cell growth for both cell types and, therefore, be 
more suitable for future in vivo application. From the proliferation results, the 1.0% PEGDA 
crosslinker gels showed continued cell proliferation for both ADSCs and DPSCs over seven days 
(Figure 2.9). These results stem from the differences in local gel/hydrogel modulus, which plays 
a critical role in cell attachment, survival, and proliferation
(29,30)
. SEM and Live/Dead images of 
the gels/hydrogels fabricated with 1.0% PEGDA crosslinker were also taken and show cell 
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attachment and spreading for the 1.0% gels overall and especially for 575 Da and 2 kDa porous 
gels with ADSCs and 2 kDa porous gels with DPSCs (Figure 2.10, 2.11, and Figure A.6). 
Taken together, along with the swelling behavior presented earlier that shows over 200% 
swelling for hydrogels prepared with 4 kDa and 8 kDa molecular weight crosslinker, it was 
concluded that 4 kDa and 8 kDa do not help promote cell spreading and survival and are not 
candidates for use as tissue engineering scaffolds. Significant swelling of 4 kDa and 8 kDa 
crosslinked hydrogels leads to poor cell morphology and communication, and overall cell death, 
as the pores continue to grow in size and cells become more isolated within the hydrogels. From 
this work, it can be concluded that 575 Da and 2 kDa 1.0% porous MTC gels are suitable for 
tissue engineering applications and can be utilized in future in vivo work for the regeneration of 
tissue in the 100 kPa modulus range such as skin, cardiac muscle, and tissues in close range like 
intestinal tissue
(132–134)
. 
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Figure 2.9: Cell proliferation trends of MTC gels/hydrogels with varying percents and length of crosslinker over 7 
days. (A) ADSCs on samples 2.5% crosslinker, (B) DPSCs on samples with 2.5% crosslinker, (C) ADSCs on 
samples with 1.0% crosslinker, (D) DPSCs on samples with 1.0% crosslinker, (E) ADSCs on samples with 0.25% 
crosslinker, and (F) DPSCs on samples with 0.25% crosslinker. All values reported as mean ± SD (n=3). 
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Figure 2.10: SEM imaging of 1.0% gels seeded without and with ADSCs after 3 days of incubation. Columns 1 and 
2 show porous gels with no cells seeded. Columns 3 and 4 show gels with ADSCs seeded after 3 days. (Columns I 
and III images at 200x magnification, scale bar= 100 µm; Columns II and IV images at 1000x magnification, scale 
bar=10 µm). 
 
 
Figure 2.11: Live/Dead cell viability imaging of 1.0% porous gels with ADSCs and 2 kDa 1.0% porous gels with 
DPSCs (far right). Cells were seeded on scaffolds for 7 days, stained, and imaged. Top row shows 3D rendering of 
cell seeded gels/hydrogels and the bottom row shows 2D captured images. 
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2.3. Conclusion 
In this work, a novel and extraordinary gel/hydrogel material was fabricated using the cyclic 
ketene acetal monomer, 2-methylene-1,3,6-trioxocane (MTC). With the unique features of this 
monomer, a degradable hydrogel was fashioned by crosslinking with poly(ethylene glycol) 
diacrylate (PEGDA). A porous, interconnected network using a sugar bead template as a mold 
was used to create samples for cell testing, taking advantage of the atypical properties of the 
monomer (liquid state) and its processability (solvent-free). As expected, the swelling, mass loss 
behavior, and mechanical properties of the MTC gels/hydrogels can be controlled by regulating 
the crosslinker concentration and the crosslinker length, which changes the hydrophilic-
hydrophobic balance within the construct. Overall through characterization of these novel MTC 
gels/hydrogels, tailorable scaffolds with superior interplay between the hydrophilicity and 
hydrophobicity demonstrated enhanced biocompatibility and can be used for tissue engineering 
application. These scaffolds have adequate mechanical properties and multiple advantages due to 
advanced degradability and ability to form porous crosslinked substrates. 
 
2.4. Experimental Section 
2.4.1. Materials 
Chloroacetaldehyde dimethyl acetal, Dowex® 50 WX-2, Tetrahydrofuran (THF), Aliquat® 336, 
diethylene glycol, Cumene hydroperoxide, and 2,2-Dimethoxy-2-phenylacetophenone, 99% 
were all purchased from Sigma Aldrich (St. Louis, MO). Potassium tert-butoxide and aluminum 
oxide were purchased from Oakwood Chemical (Estill, SC). Acrylate-PEG-Acrylate (PEG 
diacrylate) MW 2,000 was purchased from Laysan Bio, Inc. (Arab, Alabama). PEGDA 4000 and 
PEGDA 8000 were purchased from Polysciences, Inc. (Warrington, PA)  
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2.4.2. Synthesis of 2-methylene-1,3,6-trioxocane (MTC) 
The synthesis of methylene trioxocane followed the work described by Hiraguri
(112)
 et. al. and 
later Undin
(51)
 et. al. based on the method developed by Bailey
(47,48)
 et al. Briefly, 
Chloroacetaldehyde dimethyl acetal and diethylene glycol were mixed in a 1:1 ratio in the 
presence of Dowex® 50 (H
+
) in a round bottom equipped with a fractioning column. The 
mixture was heated to 120 C until the calculated theoretical amount of methanol was collected. 
The reaction was vacuum filtrated to remove the Dowex® and purified by vacuum distillation 
yielding white crystals of 2-chloromethyl-1,3,6-trioxocane (1). The monomer (1) was placed in a 
round bottom flask and dissolved at a ratio of 1:2 g/mL of anhydrous THF and placed in an ice 
bath. To this, 2 mol % of Aliquat® 336 was added and stirred for an additional 30 min in an ice 
bath. To this, 2 mol equivalents of potassium tert-butoxide were added slowly to the mixture and 
then allowed to stir overnight. The product was concentrated to remove the THF and dissolved in 
ethyl ether and purified using aluminum oxide. The filtrate was concentrated and dissolved in 
fresh ethyl ether and purified in aluminum oxide twice more to remove traces of tert-butoxide. 
Finally, the filtrate was purified by vacuum distillation using a 10 cm fractioning column to 
produce MTC (2) as a transparent liquid. The MTC steps were evaluated for NMR and FTIR to 
confirm synthesis as previously reported. Chloromethyl trioxocane IR (neat): 2950, 2880, 1470, 
1390, 1140, 1080 cm
-1
. 
1
H NMR (CDC13, 500 MHz): 3.49 (d, 2H, ClCH2), 3.60-4.14 (m, 8H, 
OCH2CH2OCH2CH2O), 4.83 (t, 1H, CH). Methylene trioxocane IR (neat): 2960, 2870, 1660, 
1450, 1370, 1150, 1080 cm
-1
. 
1
H-NMR (CDC13, 500 MHz):  3.69 (s, 2H, CH2=), 3.75-3.85, 
4.16-4.26 (m, 8H, OCH2CH2OCH2CH2O). 
   
51 
 
2.4.3. Bulk polymerization of MTC 
Polymerization of MTC was carried out by adding 0.5 g of MTC into a reaction vessel and 
adding 1.0% of Cumin before conducting a standard freeze-pump-thaw 3 times. The reaction 
was then allowed to polymerize at 70 °C for 1 day.   
 
2.4.4. Scanning electron microscopy (SEM) image analysis of unswollen and swollen PEGDA-
crosslinked MTC disks 
Disks of crosslinked MTC polymer were prepared with 3 different crosslinker (poly(ethylene 
glycol) diacrylate) contents utilizing four different molecular weights for material 
characterization (575 Da, 2 kDa, 4 kDa, and 8 kDa). Crosslinked MTC samples with 2.5, 1.0, 
and 0.25 mole percents of PEGDA, relative to the MTC monomer, were prepared with 0.1% 2,2-
Dimethoxy-2-phenylacetophenone (DMPA) UV initiator. 150 µl of prepared solutions were 
pipette into circular Teflon molds with dimensions of 8 mm in diameter and mm in depth. 
Following a gelation time of approximately 3 minutes, samples were removed from Teflon mold 
and cut in half. One half of the circular sample was immediately lyophilized and the other half 
was submerged in deionized water for 3 days to swell. Following 3 days in water, semicircle 
samples were removed and lyophilized. Unswollen and swollen samples were prepared for SEM 
by attaching to SEM stage holders affixed through copper tape. Samples were coated with gold 
for 120 seconds using a coating machine (Denton Vacuum Desk II) prior to SEM imaging (JEOL 
JSM-7800FLV).    
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2.4.5. Preparation of MTC gels for swelling and degradation studies 
Disks of crosslinked MTC monomer were prepared as described under the sample preparation 
for SEM. Prior to beginning the study, MTC disks were removed from the mold, washed to 
remove unreacted monomer and crosslinker, and air dried for 1 day and lyophilized. For both 
swelling and degradation studies, gel disks were submerged in phosphate buffer solution (PBS) 
pH 7.4 and kept at 37 °C. At predetermined timepoints, the samples for swelling experiments 
were completely blotted to remove excess surface water, and the mass of the samples was 
quickly weighed. For the mass loss studies, PBS was removed from the sample vial and samples 
were dried through lyophilization for about 6 hours at each time point. The dry mass of the 
sample at each timepoint was determined. The degree of swelling was determined using the 
formula: 
         ( )  (
     
  
)      
where Wd is the initial polymer mass and Ws is the weight of the swollen polymer measured at 
each time point. The percent of polymer remaining was calculated according to the formula:  
                  ( )  
    
  
     
Where Wd again is the initial polymer mass at the start of the experiment and Wdeg is the dried 
mass of the polymer measured at each specific time point. 
 
2.4.6. Rheological testing of gels 
The rheological properties of the produced gels were measured using a TA Instruments ARES 
rheometer. Parallel plates with 8 mm diameter with sandpaper modified surfaces were used for 
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all tests. The gap distance between the plates was 2.5-3 mm. A constant stress of ~50 Pa was 
applied for frequency spectrum measurements between 1-100 rad/s.  
 
2.4.7. Fourier Transform Infrared Spectroscopy (FTIR) degree of crosslinking characterization 
Fourier Transform Infrared Spectroscopy (FTIR) was used to characterize the gels/hydrogels and 
determine the degree of crosslinking as crosslinker mole percent and length were changed (and 
MTC amount stayed constant). Gels/hydrogels were crosslinked as previously described. 
Samples were then analyzed by FTIR on a Thermo Scientific Nicolet iS50 instrument with 
attenuated total reflection (ATR) attachment. The spectra were accumulated from 50 scans at 
resolutions of 1 cm
-1
. The FTIR spectra were normalized and spectra band positions and area 
were analyzed using the OMNIC software program.    
 
2.4.8. Differential scanning calorimetry (DSC) to glass transition temperature (Tg) 
Differential scanning calorimetry was carried out on a Perkin-Elmer DSC 7 differential scanning 
calorimeter. Roughly 10 mg of gel/hydrogel, PEGDA, and liquid MTC monomer sample were 
loaded into either standard aluminum sample pans or hermetic aluminum sample pans (liquid 
samples). Each sample was run separately against a reference empty aluminum sample pan. 
Samples were run according to the following program: (1) hold for 1.0 min at -80.00 °C, (2) heat 
from -80.00 °C to 150.00 °C at 10.00 °C/min, (3) Hold for 3.0 min at 150.00 °C, (4) cool from 
150.00 °C to -50.00 °C at 10.00 °C/min, (5) hold for 5.0 min at -50.00 °C, (6) heat from -80.00 
°C to 150.00 °C at 10.00 °C/min, (7) hold for 3.0 min at 150.00 °C, and (8) cool from 150.00 °C 
to -80.00 °C at 10.00 °C/min. Using Pyris software, the glass transition temperature (Tg) was 
extrapolated from the heating and cooling runs using the second heating curve (step 6). The 
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inflection point of the left and right limits were used to determine the Tg for each sample and 
compared.  
 
2.4.9. Fabrication of porous MTC gels and sterilization for in vitro cell testing 
To make a more suitable microenvironment for cell attachment, migration, and proliferation, 
porous gels were formed according to a previously established sugar porogen/leaching 
technique
(37,135)
. Sugar spheres of 250-425 µm of sieved sugar spheres where collected and 
packed into a Teflon vial with hexane and heat treated for 10 minutes at 37 °C. Following this, 
hexane was removed and the sugar template was dried under vacuum. Approximately 1.0 mL of 
the combined solutions of MTC, PEGDA, and 0.25% UV initiator was cast into the assembled 
sugar template. A mild vacuum was applied during casting to help pull the solution throughout 
the sugar template. A UV light of 365nm wavelength was again shone on the top of the Teflon 
vial until complete gelation. The sugar loaded gels were then removed from the vials, and the 
sugar template was leached away in distilled water. Gels disks were cut into 2 mm thick slices 
and subsequently punched into 5 mm diameter disks. To sterilize, samples were placed in 48-
well suspension plates (Greiner Bio-One) and submerged in 70% ethanol. A vacuum was applied 
for 10 min to remove air throughout the sample. After 30 min in ethanol on a shaker, samples 
were washed thoroughly 3 times in sterile PBS. After washing, gel samples were then soaked in 
cell medium with 15% FBS for 2 hours. Adipose-derived stem cells (ADSCs) and dental pulp 
stem cells (DPSCs) (200,000 cells/ gel scaffold) were seeded directly onto the gel scaffold in a 
minimum volume (~12 µL) for the first two hours before cell medium was added to the whole 
well. This was done to avoid having cells falling to the bottom of the plate rather than directly 
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onto the scaffold. Cell proliferation measured over the course of a week using CellTiter-Blue® 
Reagent (Promega Corporation) according to the manufacturer‘s instruction. 
 
2.4.10. Live/dead histological staining of in vitro cell testing samples 
Following 7 days of in vitro testing, cell-seeded hydrogel samples were washed in PBS 3 times, 
left unfixed, and immediately stained with Live/Dead Viability/Cytotoxicity Kit for Mammalian 
Cell (ThermoFisher Scientific) according to manufacturer‘s protocol. Samples were then imaged 
and visualized using confocal fluorescence microscopy (Nikon Eclipse C1).  
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Chapter 3. Delivery of Hydrophobic Small Molecule, Hydrophilic Small Molecule, and 
Protein Drugs from Novel 2-methylene-1,3,6-trioxocane (MTC) Hydrogels 
 
 
Prepared for publication in Journal of Controlled Release with co-authors: Navarro R*, 
Awada M, Adler N, Henry W, Tamas T, and Ma PX., ―Delivery of hydrophobic small molecule, 
hydrophilic small molecule, and protein drugs from novel 2-methylene-1,3,6-trioxocane (MTC) 
hydrogels.‖ *Both authors contributed equally to this work. 
 
3.1. Introduction 
Developing suitable and controlled drug delivery systems with tunable release kinetics for 
therapeutic agents with different properties has been a challenge within the field of 
nanomedicine. Due to the physicochemical and biological challenges posed by many drugs such 
as poor stability, low permeability, short half-life, enzymatic and proteolytic susceptibility, and 
systemic toxicity, drug delivery systems have been developed to encapsulate and deliver drugs 
using various delivery vehicles, overcoming many of the issues listed
(55,57,136)
. Through the drug 
delivery strategies created, controlled-release systems evolved as a means of tuning the 
pharmacokinetic and pharmacodynamic profiles of loaded drugs
(137)
. Overall, this control in drug 
release and encapsulation formulations leads to sustained release from a drug reservoir, 
improved drug efficacy, and better safety for the patient. Advantages in drug encapsulation are 
compared to liquid formulations that are administered through injections or intravenously, which 
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readily lead to large fluctuations in drug concentration overtime, systemic issues, and patient 
compliance. 
Hydrogels are a class of polymeric materials that have been used to satisfy the goals of 
controlled release drug delivery systems
(75)
. Hydrogels are generally defined as three-
dimensional, crosslinked networks of polymers that are able to uptake up to thousands of times 
their dry weight in aqueous solution and keep their shape when placed in solution
(78,81)
. 
Hydrogels offer a number of benefits as they relate to drug delivery. The first benefit is that they 
are largely composed of water and mimic native tissue and extracellular matrix. In this way, they 
are highly biocompatible, biomimetic, and are appropriate for biomaterials use
(81)
. The next 
advantage is that controlled drug release can be tailored and classified as diffusion-controlled, 
swelling-controlled, chemically-controlled (release dictated by reactions occurring in the 
polymer matrix), or a combination of these mechanisms. Nevertheless, it is possible to 
understand how a hydrogel performs in solution and manipulate and adjust parameters to 
develop a repeatable and reliable controlled drug delivery system. Two great disadvantages exist 
in hydrogel drug delivery systems despite their tunability. One of the disadvantages is that 
hydrogel drug release systems lack versatility in drug loading. As hydrogels are normally 
fashioned from hydrophilic polymers, they are mostly used to deliver hydrophilic drugs. 
Hydrophobic drugs, which make up about 40% of drugs already on the market and 60% of drugs 
at the research stage, are immiscible in many of the drug systems developed, which leads to poor 
drug loading
(81,138)
. Release of a variety of hydrophilic and hydrophobic molecules from the same 
system would help advance the field of drug delivery. The next disadvantage is that traditional 
hydrogels fabricated from polymers such as poly(ethylene glycol) and poly(vinyl alcohol) (PVA) 
are not inherently degradable based on their chemistry and must be made degradable through the 
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addition of enzymatically, photolytically, or hydrolytically degradable or cleavable 
linkages
(54,116,139)
. This complicates their chemistry and adds synthesis steps. Depending on the 
type of drug delivery system being fabricated and the desired properties and/or kinetics, 
degradation at a specific rate may be necessary and beneficial during the controlled release of 
therapeutics.  
The cyclic ketene acetal monomer 2-methylene-1,3,6-trioxocane (MTC) was previously 
presented as a material for tissue engineering application. This monomer is unique and 
advantageous in that it undergoes radical ring-opening polymerization (RROP) and a structure 
switching mechanism that leads to the formation of a polyester during polymerization
(49,51,112)
. 
An ester linkage in the polymer backbone allows the polymer to undergo hydrolysis and break 
down when tested in an aqueous medium in vitro or in vivo. When used in a drug delivery 
system, the ability to degrade allows for materials to be implanted or injected in vivo and 
subsequently resorb over time following release of the encapsulated drug. The presence of a 
radical during the ring-opening process of MTC allows the monomer to react with molecules 
containing alkene structures that induce crosslinking between the MTC chains. This ability to 
crosslink and form a gel/ hydrogel material lends the MTC crosslinked material produced to be 
used as a novel drug delivery system. Unlike traditional aliphatic polyesters which have high 
crystallinity and greater hardness, polymerized cyclic ketene acetals like MTC tend to have 
lower crystallinity and produce materials that are more flexible and have high elasticity, similar 
to the properties of previously developed hydrogels
(51)
. Hydrogels, just as those being fabricated 
in this work, form highly porous structures when placed in water
(77)
. This porosity supports the 
loading and release of drugs from the gel/hydrogel matrix at a rate that is dependent on the 
material-drug interaction, diffusion coefficient of the loaded drug throughout the MTC network, 
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and the physical properties of the gels/ hydrogels that can be tuned such as the mesh size. Along 
with the capacity to degrade and the ability to form robust gel/ hydrogel constructs, MTC is 
advantageous in that it exists in a liquid state and is miscible with crosslinking agents like 
poly(ethyelene diacrylate). This miscibility and liquid state allows for a one-pot synthesis 
reaction to take place as well as the ability to inject the solution to allow crosslinking in vivo. 
Finally, MTC is a more hydrophobic in its physical properties, which allows for loading of 
different drugs from the traditional hydrophilic hydrogel systems developed. 
To evaluate the utility of MTC gels/ hydrogels in drug delivery, MTC is crosslinked with 
varying concentrations and lengths of PEGDA crosslinker in a one-pot reaction as previously 
mentioned. Prior to crosslinking, small molecule drugs with different miscibilities or a 
macromolecule (protein) are also dissolved in solution or physically mixed to assess how the 
release of these distinct model therapeutics takes place from the hydrogel matrices. Long term 
release is evaluated in environments of different pHs, pH 7.4 and pH 4.0. With the information 
gathered from these studies, we show that a wider range of drugs can be delivered in a controlled 
manner from hydrogel materials and that this release behavior can be moderately tuned for 
different drugs. The injectability and possibility of crosslinking this novel hydrogel in situ is also 
demonstrated in this work for future drug delivery applications.       
 
3.2. Results and Discussion 
3.2.1. Loading and release behavior of Rhodamine-B dye from crosslinked MTC samples 
It was examined in this work whether drug loading and controlled drug release from MTC 
samples crosslinked with PEGDA can occur and how varying the crosslinker concentration, 
molecular weight, and physical properties of the drug influence this behavior. To adequately 
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characterize MTC for use as a drug delivery system, a range of crosslinker concentrations and 
molecular weights that change the hydrogel from a weaker material to a more rigid material were 
selected, building on the concentrations tested in the previous MTC tissue engineering work. The 
crosslinker concentrations tested include 1.0, 2.5, 5.0, 7.5, and 10 mole percents, with respect to 
moles of MTC monomer, and crosslinker lengths of 575 Da and 2, 4, and 8 kDa; a reasonably 
broad spectrum of parameters were selected to characterize release from the MTC hydrogels and 
determine the tunability of this drug release system. For the sake of visually observing the 
loading and release capability of MTC hydrogels, the pink-red dye Rhodamine was conjugated to 
2000 g/mol poly(ethylene glycol)- amine (HO-PEG-Amine), in order to prevent rapid leaching 
and aid in solubility, and incorporated into the crosslinked MTC hydrogel matrix (Figure 3.1). 
Using 1.0% crosslinked samples, PEG-Rhodamine was successfully incorporated into the 
hydrogel matrices as seen in the color change and even distribution within the clear samples. 
Samples were placed in vials of phosphate buffer saline (PBS) at pH 7.4. Within an hour, 
differences in the release behavior can be seen among the samples with respect to the crosslinker 
length. Visually, a change in the buffer solution is seen as the Rhodamine dye is released from 
the hydrogel samples. There is seemingly more rapid release of the loaded PEG-Rhodamine as 
the crosslinker length is increased; this effect is evaluated and quantified using models drugs in 
the remainder of this work. 8 kDa crosslinked samples seem to show a delayed release, however. 
It is presumed that water takes longer to penetrate these samples and fully saturate the disks from 
their initial glassy and more rigid states, which could also observed previously in Chapter 2. 
Because of this, the loaded PEG-Rhodamine B is well entrapped within the PEGDA-MTC 
matrix and released slowly at early timepoints. The apparent release trend among the 575 Da, 2 
kDa, and 4 kDa samples is supported from the discussion in the MTC tissue engineering work 
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that changes in the hydrophilicity-hydrophobicity balance dictate the behavior within these 
crosslinked structures. In this analysis, a greater molecular weight (length) in the crosslinker 
increases the hydrophilicity and leads to more rapid release early on. Knowing that MTC 
hydrogel matrices can adequately load and release through PEG-Rhodamine, the tailorability, 
through changes in the crosslinker concentration and length, and control of this drug delivery 
system was further characterized. 
 
Figure 3.1: Demonstration of drug release from 1% crosslinker MTC-PEGDA hydrogels loaded with Rhodamine-B 
dye. 
 
3.2.2. Drug release behavior based on the crosslinker molecular weight and concentration of the 
small molecule hydrophobic drug from crosslinked MTC samples 
Following confirmation of the ability to load and release molecules through testing of the PEG-
dye from the 1.0% gels, a comprehensive release test was carried out, determining the release 
behavior at the selected crosslinker concentrations and molecular weights. Two different small 
molecule drugs were used to determine how the release kinetics can vary from this hydrophobic 
crosslinked monomer and if this crosslinked MTC hydrogel drug delivery system is suitable for 
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different drug types. Simvastatin was selected as the small molecule model hydrophobic drug 
(logP = 4.68) and Aspirin was selected as the small molecule model hydrophilic drug (logP = 
1.19)
(140,141)
. Drug release was also evaluated at two different pHs to assess any changes that 
occur as pH is varied. The differences seen in release trends due to all of the different parameters 
mentioned are discussed only in terms of quantitative kinetic models (R
2
 and K values) and their 
curve fitting.  
From Simvastatin release tests, differences in release behavior are seen with respect to 
crosslinker molecular weight (length) and pH. The first notable trend is that at pH 7.4, 
Simvastatin shows minimal burst release and seemingly consistent linear release over an 
extended 10 week release period. The release kinetics are evaluated for zero-order (linear) and 
first order behavior, with all of the curve fitting included in Appendix B with and without the 
early ―burst‖ release timepoints during the first week of release. Developing drug delivery 
systems with zero order release kinetics has been a challenge among scientists and engineers, 
which makes it intriguing to see trends leaning towards this behavior in this MTC delivery 
system. A zero-order release system is one that does not show an extended burst release, delayed 
release, or an inconsistency in drug release over time
(142,143)
. Zero-order release kinetics indicates 
that the release of drug is only a function of time and release takes place at a constant rate that is 
not dependent on factors such as the drug concentration. This behavior can be modeled by the 
equation: 
         , 
where Ct is the amount of loaded drug released by time t, C0 is the initial concentration of drug 
release, which in an ideal system would be 0, and K0 is a release rate constant. This type of 
kinetics is desired because of the consistency it provides in terms of the amount of drug 
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measured in the blood or in tissue at a specific time and the ability to keep more patients in the 
therapeutic window. These systems and precisely predicting drug concentrations are difficult to 
achieve largely because of diffusion and other factors such as dissolution, partitioning, swelling, 
and erosion
(144)
. Evaluating zero-order release is done using graphs of cumulative amount of drug 
released versus time and finding the R
2
 values for a linear regression. Even with variations in the 
crosslinker concentration and molecular weight, the majority of drug release curves of 
Simvastatin from the MTC hydrogels remains linear and zero-order (Table 3.1). Although first 
order can be considered in the 575 Da pH 7.4 release test based on the R
2
 values, the curve 
fitting does not follow the first order graphs as closely, with nonlinear curve behavior appearing 
in the graphs at later timepoints. First order release is represented by the equation: 
           
  
     
 , 
where C0 is the initial concentration of drug, K is the first order rate constant, and t is the time. 
By graphing the log cumulative percent drug remaining versus time, first order behavior can be 
evaluated and quantified with the R
2
 value of the linear regression, with the slope being equal to 
-K/2.303
(145)
. From the curves of cumulative drug release versus time, comparing the crosslinker 
molecular weight extremes of 575 Da and 8 kDa, the zero-order linear regression R
2
 values are at 
0.9529 or greater when including all of the timepoints (Figure 3.2 and Table 3.2). Based on the 
amount of drug released over time amongst the 575 Da and 8 kDa samples (K0 constant), an 
average of 23 µg/day is released from 575 Da samples and an average of 33 µg/day is released 
from 8 kDa samples. This daily drug amount can be scaled up for the in vivo release of similar 
small molecule hydrophobic drugs. 
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Table 3.1: Kinetics data of Simvastatin drug release from 575 Da crosslinked samples at pH 7.4. 
 
 
Table 3.2: Kinetics data of Simvastatin drug release from 8 kDa crosslinked at pH 7.4. 
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Figure 3.2: Release kinetics graphs of Simvastatin from 575 Da and 8kDa MTC hydrogels. Graphs (A) and (C) 
show zero-order and first order release kinetics, respectively, of 575 Da samples. Graphs (B) and (D) show zero-
order and first order release kinetics, respectively, of 8 kDa samples. 
 
 A unique trend is also seen consistently in the drug release experiments performed where, 
as crosslinker concentration is increased in the samples crosslinked with 575 Da PEGDA, there 
is an increase in the amount of drug release over time. This trend is seen clearly in the theoretical 
cumulative percent release graph for Simvastatin (Figure 3.3). This reverse release behavior, 
exclusive to samples crosslinked with 575 Da PEGDA, is in line with the hydrophobicity and 
hydrophilicity argument presented in the MTC tissue engineering work in Chapter 2. Generally, 
as the percent of crosslinker is increased, mesh size decreases, which should inhibit or the slow 
the rate of drug release
(119)
. Instead, as the concentration of 575 Da crosslinker is increased from 
1% to 10%, a greater release rate is seen as the amount of crosslinker increases. This suggests 
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that at this lower molecular weight, as the 575 Da MTC samples become more hydrophilic, this 
leads to an increase in the hydrophilicity of the hydrogel which increases the rate of drug release 
from the MTC matrix. The change in hydrophilicity for this hydrophobic crosslinked MTC 
material is significant enough to drive drug release. A greater difference in the release rate as the 
percent of crosslinker is changed is also seen between the release curves of Simvastatin from 
MTC samples crosslinked with 575 Da PEGDA in pH 7.4 buffer. 
 
Figure 3.3: Unique release trend in 575 Da crosslinked MTC hydrogels. Theoretical percent released drug over time 
shows an increase in drug release as crosslinker concentration increases.  
 
The cumulative percent release graphs of Simvastatin in pH 7.4 PBS show a more 
classical release trend in the 2 kDa, 4 kDa, and 8 kDa crosslinked samples where the trend is the 
greater the crosslinker concentration, the less drug release over time. This suggests that a longer 
crosslinker causes the drug release behavior of MTC hydrogels to mimic that of typical 
hydrogels fabricated from hydrophilic monomers or polymers. The hydrophilic effect of 
changing the crosslinker length, however, can still be evaluated by noticing the change in the 
slope of cumulative percent release graphs, which is related to K0 of the cumulative amount of 
drug released graphs, as the crosslinker molecular weight is increased from 2 kDa, 4 kDa, and 8 
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kDa. When crosslinked with 2 kDa PEGDA crosslinker, the average slope of the theoretical 
percent released curves is 0.6924 ± 0.1437 (%/day). As the crosslinker length increases to 4 kDa, 
the average slope of the curves increases to 0.9377 ± 0.1209, and for 8 kDa, the average slope is 
1.3572 ± 0.1350. This means that as molecular weight of the crosslinker increases and the 
samples become more hydrophilic, there is an overall effect on how quickly the drug is released. 
A longer crosslinker in turn leads to a faster release rate of Simvastatin from the MTC hydrogels. 
The difference in release rate, however, as crosslinker concentration is increased becomes less 
pronounced as crosslinker length is increased. This can be seen in comparing the concentration 
extremes (1% and 10%) of Simvastatin released from 2 kDa and 8 kDa MTC samples (Figure 
3.4). In general, at the crosslinker concentrations tested in this drug delivery strategy, the 
variation in crosslinker mole percent with respect to moles of MTC from 1%, 2.5%, 5%, 7%, and 
10% appears to not influence drug release as greatly as changing the crosslinker molecular 
weight.  
 
Figure 3.4: Change in release rate differences as crosslinker length is increased. 1% and 10% curves for 2 kDa (left) 
and 8 kDa (right) crosslinked samples shown. 
 
 While the release tests were performed at physiological pH (pH 7.4), samples cut from 
the same initial disk prepared for each crosslinked MTC combination were also tested at an 
acidic pH of 4.0. Evaluating drug release at this pH is important when characterizing the utility 
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of drug delivery systems as different areas of the body and different disease states have more 
acidic pHs, such as the stomach or tumor microenvironment 
(146,147)
. Upon testing at pH 4.0, 
differences in the release trends were observed for the model hydrophobic drug Simvastatin 
compared to the release behavior that takes place at pH 7.4 (Figure 3.5). Looking at the 1%, 5%, 
and 10% crosslinker concentration curves for 2 kDa PEGDA crosslinker samples, notable 
changes in the slopes or release rates for each percent at pH 4.0 can be seen when compared to 
the release rate achieved at pH 7.4 (Table 3.3). The drug release is severely dampened in the 
acidic PBS buffer. The remaining crosslinker lengths (575 Da, 4 kDa, and 8 kDa) also follow 
this trend when comparing release at pH 7.4 and pH 4.0, with shallower slopes and slower 
release occurring in an acidic environment. This change is slope is also reflected in a drop in the 
K0 values when comparing the zero-order release kinetics at the two pHs tested (Table 3.4 and 
Table 3.5). With both zero-order and first order behavior at play following a more pronounced 
burst order than at pH 7.4, the curves for cumulative percent of drug released over time at pH 4.0 
tends towards behavior that suggests that both the time-independent release kinetics 
characteristic of swelling-controlled drug release and kinetics of the diffusion process are driving 
drug release; this situation is known as anomalous transport
(148)
. Detailed modeling, however, 
should be used to verify the type of release mechanism by finding the value of the diffusion 
coefficients, which falls into specific ranges depending on the diffusion mechanism. The change 
in release kinetics and potentially release mechanism and why this occurs in acidic pH for this 
MTC hydrogel system crosslinked with PEGDA is not completely understood at this time. 
Where generally an acidic pH enhances degradation and swelling of most polymers and should, 
therefore, lead to a greater amount of drug released at each timepoint compared to the release at 
pH 7.4, the opposite effect is seen consistently in this work. It is hypothesized based on the 
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shallow release that there is a shrinking or deswelling effect on the MTC hydrogels, causing a 
shrinking in the pores of the hydrogel mesh and retardation in the release of the loaded small 
molecule drug. This hypothesis can be verified through future swelling tests of the MTC samples 
at the crosslinker concentration used in this drug delivery work in acidic PBS buffer. The change 
in mesh size can also be evaluated visually using SEM, as previously shown in the MTC tissue 
engineering work, and more robustly using fluorescent dextran beads
(149,150)
. 
 
Figure 3.5: Simvastatin release at physiological pH versus at acidic pH from 2 kDa crosslinked MTC samples. Drug 
release is shown at pH 7.4 (left) and pH 4.0 (right) at varying crosslinker concentrations. 
 
Table 3.3: Change in slope/drug release rate of Simvastatin at pH 7.4 versus pH 4.0 at different 
crosslinker concentrations. 
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Table 3.4: Kinetics data of Simvastatin release from 2 kDa crosslinked MTC samples at pH 7.4. 
 
 
Table 3.5: Kinetics data of Simvastatin release from 2 kDa crosslinked MTC samples at pH 4.0. 
 
 
 While Simvastatin was able to show long-term release from the hydrophobic crosslinked 
MTC, Aspirin did not perform well in this drug delivery system. Although Aspirin appeared 
soluble and dissolved directly into the solutions of MTC, PEGDA, and initiator prior to 
crosslinking, close to 100% of drug was released within 24 hours (the first two measured 
timepoints) at both pH 7.4 and pH 4.0. This effect is similar to how hydrophobic drugs fail to 
show sustained release in traditional hydrogel drug delivery systems fabricated from hydrophilic 
monomers or polymers
(77)
. Aspirin acts as a negative control for this drug delivery system, 
further showing the benefit of this hydrogel matrix for loading and delivery of the numerous 
hydrophobic drugs.    
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3.2.3. Drug release behavior based on the crosslinker molecular weight and concentration of 
BSA loaded protein 
The release behavior of Bovine Serum Albumin (BSA), a globular protein, was also evaluated 
from this MTC drug delivery system. BSA was loaded at the same concentration as Simvastatin 
and Aspirin and evaluated at physiological pH and at an acidic pH as the crosslinker 
concentration and molecular weight were varied. It is important when characterizing this novel 
drug delivery system to compare the release behavior of the small molecule drugs previously 
discussed to that of a protein such as BSA not only because of the physical hydrophilic 
properties of proteins, but also because of the great difference in the size of the molecules. 
Simvastatin and Aspirin, with molecular weights of 418.6 Da and 180.16 Da, respectively, are 
classified as small molecule drugs as they are organic compounds that are less than 900 Da
(151)
. 
BSA, on the other hand, is much larger with a molecular weight of 66.5 kDa and is expected to 
behave differently when eluting from a hydrogel system. Representative of the release kinetics of 
BSA from all of the MTC combinations tested, the graphs of BSA release at pH 7.4 and pH 4.0 
from samples crosslinked with 575 Da PEGDA indicate the release behavior of this protein 
(Figure 3.6). Unlike the steady and linear release Simvastatin shows at pH 7.4 and the complete 
dumping of Aspirin under all conditions that takes place within 6-24 hours, BSA consistently 
shows burst release behavior over the first 3-7 days of release followed by slower steady release. 
The greater the crosslinker concentration the faster the drug or protein is completely released. 
Following the first week of drug release, at all of the crosslinker lengths tested, release at pH 7.4 
continues at more first order kinetics for samples with a lower crosslinker concentration, while 
release at pH 4.0 shows evidence of zero-order release at these same crosslinker concentrations 
in the upward linear slope of the curves. The kinetics at pH 7.4 (Table 3.6) and at pH 4.0 (Table 
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3.7) (minus the 10% curves) were evaluated through the zero-order and first order R
2
 values with 
and without the burst release values up to day 3. BSA release at pH 7.4 displays consistent first 
order release behavior, whereas BSA release at pH 4.0 shows first order release within the first 7 
days followed by an apparent change in release that can be classified as zero-order release for the 
remaining time of the experiment. As previously mentioned when discussing Simvastatin, 
modeling should be used in the future to find the value of the diffusion coefficients and 
determine the release mechanism of BSA from MTC hydrogels. 
 
Figure 3.6: BSA release at physiological pH versus at acidic pH from 575 Da crosslinked MTC samples. Drug 
release is shown at pH 7.4 (left) and pH 4.0 (right) at varying crosslinker concentrations. 
 
Table 3.6: Kinetics data of BSA release from 575 Da crosslinked MTC samples at pH 7.4 with 
and without 3 day burst release timepoints. 
 
   
73 
 
Table 3.7: Kinetics data of BSA release from 575 Da crosslinked MTC samples at pH 4.0 with 
and without 3 day burst release timepoints. 
 
 
Just as in the case of release of Simvastatin from 575 Da crosslinked samples at pH 7.4, 
the release of BSA at both pHs and all four molecular weights show a reverse trend in release. 
As the crosslinker percent is increased within the hydrophobic MTC samples, instead of a 
traditional inhibition in release as the mesh size decreases with increasing crosslinker 
concentration, the release rate of BSA increases. This behavior is illustrated again looking at the 
graphs for the crosslinker molecular weight extremes (575 Da and 8 kDa) for 1%, 5%, and 10% 
crosslinker concentrations (Figure 3.7). For a hydrophilic protein encapsulated in a hydrophobic 
material this can be expected as the protein would rather move into a more hydrophilic 
environment. Therefore, as the samples become more hydrophilic with the increase in crosslinker 
concentration, BSA release rate is enhanced. It is postulated that BSA shows this same ―reverse‖ 
release pattern at both pH 7.4 and pH 4.0 despite any physical changes to the MTC hydrogels at 
different pHs because the release of the proteins from highly crosslinked hydrogels is generally 
independent of pore or mesh size
(152,153)
. As BSA is a much larger molecule than the small 
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molecule drugs discussed earlier, BSA does not travel as extensively through or get trapped and 
interact with pores within the gel matrix as closely as a small molecule like Simvastatin. Instead, 
proteins may diffuse through hydrogels based on theories such as the free volume theory, which 
describes how high molecular weight molecules (proteins/drugs) diffuse by jumping into 
previously occupied voids in a polymer (solvent) system
(154,155)
. Changes in the hydrogel 
morphology or pore size and any related changes in material surface charge and charge 
interactions, however, can be evaluated to rationalize the consistent differences in kinetics 
between the more flat release curves seen at pH 7.4 and the upward sloping linear release seen at 
pH 4.0.  
 
Figure 3.7: Reverse trend in drug release: increase in BSA release as crosslinker concentration is increased. (A) 
BSA release from 575 Da samples at pH 7.4, (B) BSA release from 575 Da samples at pH 4.0, (C) BSA release 
from 8 kDa samples at pH 7.4, and (D) BSA release from 8 kDa samples at pH 4.0 at 1%, 2.5%, and 10% 
crosslinker concentrations. 
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Finally, the BSA release experiments did not show any substantial trends with respect to 
crosslinker molecular weight. This can be due to how BSA interacts with the MTC hydrogel 
matrix as well as how changes in crosslinker molecular weight versus changes in the crosslinker 
concentration tested influence changes in sample hydrophilicity.  
 
3.2.4. Testing in situ injectability of MTC hydrogels  
The ability to inject the MTC-PEGDA solution subcutaneously into a mouse prior to forming the 
robust hydrogel biomaterial was tested. To assess the injectability, the 2 kDa 1.0% PEGDA 
crosslinker MTC hydrogel formulation was injected at volumes of 100 µL to 250 µL 
subcutaneously into a euthanized mouse using a standard 18G needle, assisted by a colleague 
Zhen Zhang. The minimum amount of time needed for gelation under the 365 nm wavelength 
UV light was also tested. The goal was to show that the MTC solution could successfully pass 
through a needle, collect in a subcutaneous pocket, and gel through the mouse skin in situ to 
potentially deliver a drug. From the trials done, injecting 100 µL and administering the UV light 
for 1 minute help form a complete and contained gel reservoir (Figure 3.8). A larger volume or 
less time (30 seconds) for gelling leads to spreading of the material under the skin of the mouse, 
which could cause the material to be washed away and drug being released away from the 
intended site of action. Injectability is desirable for hydrogels, whether used for drug delivery or 
tissue engineering, because it allows for minimally invasive in situ delivery of therapeutic agents 
or a tissue engineering scaffold
(156)
. Traditionally, hydrogels have been formed at the bench, 
sterilized, and implanted using an invasive surgical process. With the advent of injectable 
hydrogels, novel hydrogels developed should meet this criterion of injectability as they help 
reduce procedure costs, diminish pain to the patient, and protect the drug payload being delivered 
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in vivo. Improving the gelation in future experiments to possibly reduce the time of UV light 
exposure and help prevent the gel from flowing away could be achieved using a probe or point 
source light rather than a larger UV light available for these experiments. Formulations with 
higher molecular weights that have a slightly higher viscosity may also better form intact drug 
depots in situ.  
 
Figure 3.8: Testing injectability of MTC hydrogel through subcutaneous injection and gelling in situ into mouse. 
(A) Subcutaneous pocket of gel formed, (B) 100 µL MTC solution and 30 seconds gelling, (C) 100 µL MTC 
solution and 1 minute gelling, and (D) 250 µL and 1 minute gelling. 
 
3.3. Conclusion 
The utility and biocompatibility of MTC gels/ hydrogels have been previously shown for tissue 
engineering purposes. Here, MTC was adapted and characterized for use as a drug delivery 
system for the release of small molecule hydrophobic drugs, small molecule hydrophilic drugs, 
and proteins. Based on different parameters including the crosslinker molecular weight, 
crosslinker concentration, physical properties of the molecule being delivered, and the delivery 
environment (pH), different trends were found. Overall, this drug delivery system appears highly 
suitable for the long-term delivery of small molecule hydrophobic drugs, such as the model drug 
Simvastatin, and is also suitable for the release of proteins, such as BSA, tested in this work. 
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This system was not ideal for the release of Aspirin, a small molecule hydrophilic drug, which 
showed rapid, uncontrolled release. Simvastatin release curves showed zero-order release 
behavior at physiological pH, while at an acidic pH of 4.0 this release was stifled. Hydrophilic 
effects were seen in crosslinked concentration and molecular weight and reflected in the drug 
release rate as discussed. Similarly, the release of BSA showed a dependence on crosslinker 
concentration especially, with a consistent increase in the amount of drug released over time as 
crosslinker concentration was increased. The greatest challenge in future protein release, as in 
many drug delivery projects, is reducing the initial burst release. An understanding of how 
different molecules interact with this novel drug delivery system was attained through these 
experiments. By tailoring the transport and physical characteristics of the components of this 
drug delivery system, it shows great potential for injectable, controlled release applications of 
hydrophobic drugs and proteins. 
 
3.4. Experimental Section 
3.4.1. Materials 
Chloroacetaldehyde dimethyl acetal, Dowex® 502W, Tetrahydrofuran (THF), Aliquat® 336, 
diethylene glycol, Rhodamine-B, MES, and 2,2-Dimethoxy-2-phenylacetophenone, 99% were 
all purchased from Sigma Aldrich (St. Louis, MO). Potassium tert-butoxide and aluminum oxide 
were purchased from Oakwood Chemical (Estill, SC). N-(3-Dimethyaminopropyl)-N‘-
Ethylcarbodiimide (EDC) Hydrochloride was purchased from Advanced Chemtech. Acrylate-
PEG-Acrylate (PEG diacrylate) MW 2,000 and HO-PEG-Amine 2000 were purchased from 
Laysan Bio, Inc. (Arab, Alabama). PEGDA 4000 and PEGDA 8000 were purchased from 
Polysciences, Inc. (Warrington, PA). The drug Simvastatin was purchased through Acros 
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Organics, Aspirin was purchased through Sigma Aldrich, and Bovine Serum Albumin Standard 
Grade was purchased through Alkali Scientific Inc.  
 
3.4.2. Synthesis of 2-methylene-1,3,6-triococane (MTC) 
The synthesis of methylene trioxocane followed the work described by Hiraguri
(112)
 et. al. and 
later Undin
(51)
 et. al. based on the method developed by Bailey
(47,48)
 et al. Synthesis is identical to 
the process used in the tissue engineering MTC gel/ hydrogel work. Briefly, Chloroacetaldehyde 
dimethyl acetal and diethylene glycol were mixed in a 1:1 ratio in the presence of Dowex® 50 
(H
+
) in a round bottom equipped with a fractioning column. The mixture was heated to 120 C 
until the theoretical amount of methanol was collected. The reaction was vacuum filtrated to 
remove the Dowex® and purified by vacuum distillation yielding white crystals of 2-
chloromethyl-1,3,6-trioxocane (1). The monomer (1) was placed in a round bottom and dissolved 
at a ratio of 1:2 g/mL of anhydrous THF and placed in an ice bath. To this, 2 mol % of Aliquat® 
336 was added and stirred for an additional 30 min in an ice bath. To this, 2 mol equivalents of 
potassium tert-butoxide were added slowly to the mixture and then allowed to stir overnight. The 
product was concentrated to remove the THF and dissolved in ethyl ether and purified using 
aluminum oxide. The filtrate was concentrated and dissolved in fresh ethyl ether and purified in 
aluminum oxide twice more to remove traces of tert-butoxide. Finally, the filtrate was purified 
by vacuum distillation using a 10 cm fractioning column to produce MTC (2) as a transparent 
liquid.  
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3.4.3. Fabrication of MTC drug loaded samples 
Disks of crosslinked MTC polymer with loaded drug were prepared with five different 
crosslinking percents of poly(ethylene glycol) diacrylate and utilizing four different molecular 
weights (575Da, 2kDa, 4kDa, and 8kDa). 1.0%, 2.5%, 5.0%, 7.5%, and 10.0% mole percent of 
crosslinked MTC samples were prepared with 0.1% 2,2-Dimethoxy-2-phenylacetophenone 
(DMPA) UV initiator. Crosslinker was dissolved within MTC solution with added heat at 55°C, 
if necessary. Small molecule hydrophobic drug (Simvastatin), small molecule hydrophilic drug 
(Aspirin), and a model protein (Bovine Serum Albumin- BSA) were loaded at 3 weight/volume 
percent to determine changes in release behavior of different types of drugs. Simvastatin and 
Aspirin were dissolved directly into the MTC monomer, while BSA was dissolved at 2 µg/µl in 
distilled water and added to MTC. MTC monomer, dissolved crosslinker, added drug, and 
DMPA initiator solutions were vortexed for 10 seconds for even mixing, and 1mL of solution 
was added into an 18mm Teflon vial. Samples were left for 5 minutes under 365nm wavelength 
light for complete gelation. Disks were removed from Teflon vials and left in DI water for 5 
minutes to remove unreacted solution on disk surfaces. 5 mm samples were cut from this larger 
disk for drug release testing.  
 
3.4.4. Fabrication of Rhodamine-B drug loaded samples and evaluation of release 
The dye Rhodamine-B was loaded into crosslinked MTC samples to observe how loading and 
release takes place from the hydrogel matrices. Prior to loading, Rhodamine-B was conjugated to 
HO-PEG-Amine 2000 through EDC chemistry. To do this, PEG-amine and Rhodamine-B were 
both dissolved in MES buffer pH 4.7. PEG-Amine and Rhodamine-B were reacted in a 1:3 molar 
ratio to ensure conjugation. EDC was dissolved in MES buffer and added to the reaction and left 
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to react for 24 hours. The reaction was then dialysed to remove the unreacted Rhodamine-B and 
subsequently lyophilized. Using a mold, 8 mm diameter and 2 mm thickness disks were 
fabricated utilizing four different molecular weights (575Da, 2kDa, 4kDa, and 8kDa) at 1.0% 
crosslinker concentration with 1.0% weight/volume PEG-Rhodamine-B loaded according to the 
crosslinking protocol mentioned in the previous section. Samples were then placed into 1 mL of 
DI water to observed release over time visually.  
 
3.4.5. Performing drug release test of drug loaded MTC samples 
5 mm gel/hydrogel samples were punched from 18 mm drug loaded MTC disks and placed into 
an eppendorf tube with 1 mL of phosphate-buffered saline (PBS) at either pH 7.4 or pH 4.0. At 
the desired timepoints, PBS solution was collected and gel sample was resuspended in 1 mL of 
fresh PBS until the next timepoint. To form a curve of cumulative drug released over time, 
Simvastatin and Aspirin timepoints were measured using ultraviolet-visible (UV-Vis) 
spectroscopy, measuring the drugs at their characteristics wavelengths of 247nm and 230nm, 
respectively. BSA was measured using a MicroBCA Protein Assay kit according to the 
manufacturer‘s protocol. N=3 was for all samples at both pH values tested. Theoretical drug 
loading was calculated based on the volume of the MTC disks after washing and prior to 
punching out samples, and scaled based on the amount of drug loaded into 1 mL of solution used 
for crosslinking and the volume of the 5 mm diameter samples. 
 
3.4.6. Testing injectability and gelling of MTC gel/ hydrogel 
Injectability of the MTC gel was tested using the 2 kDa 1.0% PEGDA crosslinker formulation. 
To do this, mice were euthanized via CO2 asphyxiation followed by cervical dislocation and 
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experiments were performed on dead mice. 100-250 µL of solution without drug was 
subcutaneously injected using an 18 gauge (G) needle and gelled with 365 nm wavelength UV 
light in NOD-scid mice. Various gelling times were tested to find the minimum time needed for 
complete gelation. Skin of mice was subsequently cut open and pulled back for imaging of gel 
material.  
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Chapter 4. Targeting of HER2+ SKBR3 cells with Novel Conjugated Targeting Peptides on 
“Single” versus “Palm-tree” PEG-PLGA Nanoparticles (NPs) 
 
 
Prepared for publication in Nanomedicine with co-authors: Chen J, Wang J, Cao Z, Wang 
SH, and Ma PX., ―Efficacy of linear PEGMA-PLGA versus branched PEGPET-PLGA 
nanoparticles with conjugated novel targeting peptides against HER2+ SKBR3 Breast Cancer 
Cells.‖ 
 
4.1. Introduction 
With over 268,600 new cases diagnosed in 2019 and over 41,760 deaths annually in the same 
year, breast cancer is the most common cancer diagnosed and second most common cause of 
cancer-related deaths in women in the United States 
(97,157)
. Among the types of breast cancer 
diagnosed, human epidermal growth factor receptor 2 (HER2) positive breast cancer currently 
accounts for 15-20% of all diagnosed breast cancer cases
(96,99)
. HER2+ breast cancer patients 
generally have expression of HER2 that is 50-100 fold higher in tumor cells than normal cells 
(HER2+). It is one of the most aggressive types of breast cancer, and patients faced with this 
type of breast cancer often become resistant to treatment regimens. Treatment options for 
HER2+ breast cancer includes different systemic therapy options including chemotherapy for 
highly proliferative tumors, hormonal therapy, radiation therapy, and/or HER2-targeted therapy, 
including the use of the popular anti-HER2 monoclonal antibody trastuzumab
(98)
. Significant 
disadvantages exist in the use of these systemic treatments. In particular, the use of trastuzumab 
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is limited in the number patients‘ prognoses it improves and presents challenges with 
determining the most appropriate adjuvant sequence for patients as well as the necessary 
treatment duration. Trastuzumab also poses serious cardiac toxicity effects, especially when used 
in combination with frequently used anthracycline chemotherapeutics
(158)
. Issues with these 
systemic treatments, especially chemotherapy, stem from the fact that they not only kill cancer 
cells, but also fast-growing healthy cells. Because of this many short-term and long-term side 
effects result from the systemic nature of treatments including nausea, vomiting, loss of appetite, 
fever, and fatigue along with heart, kidney, lung, and nerve dysfunction in the months to years 
following treatment. The demonstrated low-efficacy of anthracycline based treatment regimens 
and resistance of HER2+ breast cancers to these treatments contribute to an overall high 
mortality rate in HER2+ breast cancers. 
Nano drug delivery systems have been developed to address these systemic effects and 
other challenges that exist with delivering drugs into the body to treat diseases such as HER2+ 
breast cancer. These additional challenges include poor drug solubility, especially when 
delivering hydrophobic drugs like the chemotherapeutics, poor absorption by the body, lack of in 
vivo stability, and poor bioavailability/distribution
(55)
. Different nanoparticle types have helped to 
address some of these issues, such as the liposomal anthracycline formulation known as 
Doxil
(83)
. Although this liposomal doxorubicin treatment is FDA approved and decreases toxicity 
effects compared freely floating doxorubicin, the delivery of liposomal doxorubicin has failed to 
significantly improve patient treatment and prognosis compared to conventional doxorubicin 
treatment
(158)
. As with early nanoparticle systems for cancer treatment that rely solely on size and 
the enhanced permeation and retention (EPR) effect to enter tumors, Doxil and other non-ligand 
conjugated nanoparticle systems are passive targeting
(159)
. The majority of administered 
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nanoparticles in these systems fail to reach their intended site of action and are largely 
ineffective in reaching and treating tumors and any metastatic breast cancer cells. 
Instead, active targeting approaches are useful in helping nanoparticles delivered into the 
body more precisely reach HER2+ breast cancer cells and deliver drugs to the cells they are 
intended to kill. By modifying nanoparticles‘ chemistry and attaching targeting ligands such as 
with antibodies or peptides on their surface, nanoparticles can selectively interact with HER2+ 
cancer cell receptors to bind to these cells
(82,160,161)
. A number of polymeric nanoparticle systems 
designed to treat HER2+ breast cancer cells have used targeting peptides, specifically folic acid-
derived peptides, cyclic RGD, and peptide mimics of the trastuzumab antibody
(68,83,162,163)
. While 
peptides are a superior choice in targeting moiety due to their size, selectivity, risk of 
immunogenicity, ease of conjugation, and low cost of fabrication, these nanoparticle-peptide 
systems are not very effective or ideal
(160)
. Folic acid and RGD are more nonspecific peptides as 
healthy cells also express the folate receptor targeted by the folic acid peptides and the RGD 
peptide is a general cell binding sequence
(92,164)
. As with the trastuzumab antibody, targeting 
using a trastuzumab peptide-mimic shows selectivity, but limited ability to effectively treat 
HER2+ cancer. More selective and effective HER2+ targeting peptides in combination with 
drug-loaded nanoparticles must be employed to meet this treatment goal and improve 
nanoparticle delivery to and into HER2+ breast cancer cells. 
A number of targeting peptides specific to HER2+ breast cancer has have been identified 
through various screening processes over the past decade
(165,166)
. Among these, novel peptide 
sequences have been identified through phage display with high specificity for the HER2+ 
SKBR3 cell type
(167,168)
. In this work, the peptide with the greatest affinity, L1 (sequence: 
VSSTQDFP), was selected and assessed as a peptide strategy conjugated to polymeric 
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nanoparticles to target and ultimately kill HER2+ breast cancer cells. In addition to testing how 
this peptide performs as a component in a nanoparticle drug delivery system, additional 
strategies are employed to determine if they improve the efficacy of the nanoparticles to not only 
target HER2+ breast cancer cells, but also ensure internalization of the particles into cells to then 
release drug and cause cell death. The first strategy involves incorporating a cell-penetrating 
peptide (CPP) sequence to that of the L1 sequence. CPPs are short sequences, up to 30 amino 
acids, that help arrange extracellular components and overcome intracellular barriers of entry to 
facilitate the movement of cargo across the cell membrane and into the cell cytoplasm
(169–171)
. 
One of the first identified, most effective at intracellular routing, and commonly used CPPs is the 
transactivator of transcription (TAT) protein isolated from the human immunodeficiency virus 
(HIV) (sequence: GRKKRRQRRRPQ). The ability of these novel peptide combinations to 
improve nanoparticle targeting and entry into HER2+ cells and how varying position of this 
added TAT sequence (preceding or following the L1 sequence) is evaluated. The second strategy 
manipulates the nanoparticle chemistry, by (1) preliminarily determining the appropriate spacer 
length for the peptides used and (2) using this spacer length, testing mono- (poly(ethylene glycol 
methacrylate)-poly(lactic-co-glycolic acid): PEGMA-PLGA) versus multi-functionalized 
(poly(ethylene glycol) pentaerythritol triacylate -poly(lactic-co-glycolic acid): PEGPET-PLGA) 
copolymer chemistries to increase peptide presentation on the nanoparticle surface. Spacers are 
necessary to allow for peptide flexibility and interaction with the cell membrane, but cannot be 
too long as this can inhibit cell attachment
(92)
. By using this information and applying it to the 
two different chemistries, it can be determined whether more peptide presence leads to increased 
cell binding.  
   
86 
 
A number of nanotechnology approaches, namely the use of chemistries, nanoparticles, 
targeting ligands, and their individual modifications, are used in this work to improve and test 
this HER2+ targeted drug delivery strategy. The hypothesis is that nanoparticles fabricated from 
the novel multi-functionalized ―palm-tree‖ structured PEGPET-PLGA copolymer conjugated 
with a combined targeting and internalization peptide sequence will show increased nanoparticle 
uptake and subsequent cell death compared to the ―single‖ nanoparticles fabricated from 
PEGMA-PLGA. A series of peptides (L1, L1-TAT, and TAT-L1) are conjugated through a click 
chemistry reaction to the surfaces of the two different nanoparticle types produced. From the in 
vitro targeting affinity and cell viability/cell death experiments completed and outlined in this 
work, a platform is established to improve treatment of invasive HER2+ breast cancer. 
 
4.2. Results and Discussion 
4.2.1. Fabrication of Poly(ethylene glycol) methacrylate – Poly(lactic-co-glycolic acid) 
(PEGMA-PLGA)  nanoparticles and testing of appropriate PEGMA peptide spacer 
length 
Initially in this work, PEGMA-PLGA nanoparticles were fabricated to test the efficacy of the 
newly identified L1 peptide in targeting and treating HER2+ SKBR3 cells. The PEGMA-PLGA 
copolymer, where the PEG segment serves as the peptide spacer, was synthesized as outlined in 
the methods section. Using this copolymer, nanoparticles identified as ―single‖ nanoparticles 
(SNPs) or PEGMA-PLGA nanoparticles were developed using a standard water/oil/water 
(w/o/w) double emulsion process. Following fabrication, the peptide was conjugated to the 
nanoparticle by reacting with the surface PEGMA polymer component. While synthesizing the 
PEGMA-PLGA copolymer is not unique to this work, conjugation of this specific peptide 
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through a thiol-ene ―click‖ chemistry reaction had not been previously explored. To facilitate this 
reaction, peptides were purchased with a modification adding a Cysteine amino acid to the C-
terminus to take advantage of the thiol (-SH) functional group available with this amino acid. It 
was then important within this fabrication to determine the ideal PEGMA spacer length for 
peptides within this range of molecular weight/# of amino acids (983 Da, 9 amino acids). PEG 
and its derivatives have been previously used for the purpose of serving as a peptide spacer 
which helps improve peptide stability in solution, but is also beneficial in nanoparticle work to 
impart a stealth layer to particles and reduce uptake by immune cells
(82,172–174)
. 1 kDa, 2 kDa, and 
10 kDa PEGMA spacers were selected and tested based on guidance from the literature
(172,175,176)
. 
Using confocal microscopy imaging and Rhodamine-B loaded particles, 1 kDa and 2 kDa spacer 
particles both showed similar L1 conjugated nanoparticle uptake (Figure 4.1). As 2 kDa 
PEGMA-PLGA nanoparticles showed a consistent slight increase in uptake as analyzed using 
ImageJ (3-5%) compared to 1 kDa spacer particles, 2 kDa PEGMA was selected to proceed with 
all of the particle formulations and remaining experiments. Particles with 10 kDa spacer showed 
poor uptake overall as expected based on the literature.  
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Figure 4.1: Nanoparticle PEG spacer length testing. 1 kDa, 2 kDa, and 10 kDa PEGMA spacers (rows) tested on 
L1, scrambled peptide (negative control), and TAT (positive control) conjugated nanoparticles. 
Through SEM, the PEGMA-PLGA particles were then visualized, and using dynamic 
light scattering (DLS), the average diameter of the particles was also measured and found to be 
645.4 nm (Figure 4.2). Through FITC-labeling of the peptide and confocal imaging, there was 
confirmation of peptide conjugation onto to the PEGMA-PLGA nanoparticles as seen on the 
perimeter of the individual particle (Figure 4.3a). Using this same nanoparticle formulation with 
FITC-labeled L1 peptide, preliminary testing of the L1 peptide on the PEGMA-PLGA 
nanoparticles for their cell binding was done against SKBR3 cells, which are HER2+ breast 
cancer cells, and MCF7 cells, which are HER2- breast cancer cells used as a negative control. 
Greater uptake is seen in the target SKBR3 cells, where more minimal uptake is seen in the 
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MCF7 cells (Figure 4.3b). The L1 peptide was screened in the literature against MCF10A cells, 
which are HER2- breast cancer cells as a negative control
(167)
. Testing these conjugated particles 
against MCF7 cells here further shows good peptide specificity to continue this nanoparticle 
work.  
 
Figure 4.2: Imaging and size evaluation of PEGMA-PLGA nanoparticles. SEM was used to visualize PEGMA-
PLGA nanoparticles (left) and dynamic light scattering (DLS) was used to determine the mean particle diameter. 
Scale bar= 1µm. 
 
Figure 4.3: Confocal imaging of peptide conjugated PEGMA-PLGA ―single‖ nanoparticles (SNPs). (A) Confocal 
image of individual FITC-labeled L1 conjugated SNPs at 4x (left) and 20x (right) magnifications, and (B) Testing of 
peptide L1 conjugated SNPs against HER2+ SKBR3 cells and HER2- MCF7 cells. Cell nuclei labeled with DAPI. 
 
4.2.2. Peptide affinity and dosage testing of “single” PEGMA-PLGA nanoparticles 
Peptide affinity was more robustly tested using flow cytometry to quantify the degree of cell 
targeting or binding by the peptide conjugated SNPs. This experiment was also used to discover 
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any dose dependency on cell binding and to test the material toxicity as these nanoparticles do 
not contain a therapeutic and should not inherently cause cell death or significantly affect cell 
viability. The goal of this experiment was settling on an optimal dose for further in vitro testing. 
Peptide affinity was assessed by measuring the increase in fluorescence intensity as particle 
binding occurs, which is measured along the x-axis of histogram plots produced from flow 
cytometry runs. This is always compared to untreated control cells, and the percentage recorded 
represents the percent of particle-bounce cells with increased fluorescence as measured in in a 
specific fluorescent channel (i.e. FITC, Rhodamine/PE).The corresponding scatter plots allow for 
gating or selecting by the user for a specific population in the sample, which are generally the 
live cells. Although FITC-labeled peptide was used for confocal microscopy, this was not found 
to be a reliable detection method because, as previously noted in the literature, there was great 
batch-to-batch differences in peptide conjugation
(177)
; some batches of L1 peptide displayed less 
than 10% FITC conjugation as confirmed through high-performance liquid chromatography 
(HPLC) performed by Lydia Atangcho in the Thurber Laboratory (UMich). With a low amount 
of dye conjugation, cell binding could be taking place that is not being measured due to a lack of 
fluorescence signal. FITC is also documented as having poor photostability in buffer
(178)
. Instead 
Rhodamine-B loaded PEGMA-PLGA nanoparticles were used as the dye is loaded 
homogenously through a double emulsion. This loading with Rhodamine-B led to fewer issues 
with batch-to-batch variability compared to the conjugation of FITC to the peptide, as a loading 
efficiency of ~70% is steadily achieved for this small molecule. A single batch of Rhodamine-
loaded nanoparticles could also be used for multiple experiments. From the flow cytometry 
results, run and compiled by collaborator Jesse Chen in Prof. SuHe Wang‘s laboratory (UMich), 
a dose dependent shift is in fact seen (Figure 4.4). At a concentration of 0.5 mg/mL of peptide 
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conjugated PEGMA-PLGA nanoparticles, there was a 4 times increase in Rhodamine-B 
fluorescence (22.10%) when incubated with L1 particles compared to untreated cells (4.97%), 
which leads to the assumption that L1 is binding to the SKBR3 cells. When this concentration 
was increased to rule out higher concentrations, a clear decrease in cell viability was seen 
through the scatterplots produced (Figure C.1). Based on this dosage and toxicity testing, the 0.5 
mg/mL particle concentration was established as the concentration to be used moving forward. A 
scrambled negative control peptide, designated as L1c (sequence: SDPQVFSTC) was evaluated 
at the same particle concentration of 0.5 mg/mL and showed no specific binding, essentially with 
similar fluorescence readouts to the untreated cells at 5.69% and 4.33%, respectively (Figure 
4.5). As a negative control, this means there are not any non-specific effects for L1 conjugated 
nanoparticle binding and it is due to peptide sequence specificity. 
 
Figure 4.4: Flow cytometry affinity and dose testing of L1 conjugated PEGMA-PLGA ―single‖ nanoparticles 
(SNPs) against HER2+ SKBR3 cells. (A) Untreated cells, (B) Cells tested at a particle concentration of 0.5 mg/mL, 
(C) Cells tested at a particle concentration of 0.25 mg/mL, and (D) Cells treated at a particle concentration of 0.125 
mg/mL. 
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Figure 4.5: Flow cytometry affinity dose testing of L1c conjugated PEGMA-PLGA nanoparticles (SNPs) against 
HER2+ SKBR3 cells. (A) Untreated cells and (B) Cells tested at a particle concentration of 0.5 mg/mL. 
 
 
4.2.3. Ligand strategy to improve nanoparticle targeting and uptake through combination 
peptide sequences 
While targeting was achieved with L1 conjugated PEGMA-PLGA nanoparticles, strategies were 
applied to test whether the targeting and internalization can be amplified. The first way in which 
this was done was by creating combination peptide sequences that incorporated a cell-penetrating 
peptide (CPP) sequence. In this way, a small library of peptides was created for testing (Table 
4.1).  The TAT sequence, described in the introduction, has been extensively used as a CPP due 
to its high solubility and ability to penetrate a multitude of cells
(179)
. This sequence was used in 
conjunction with the L1 sequence either following or preceding the TAT sequence to test 
whether HER2+ targeting specificity can be maintained and increased nanoparticle 
internalization can be achieved using these specific combination peptide sequences. Conjugating 
L1 and TAT separately onto the same nanoparticle surface would be futile in achieving this goal 
as TAT is a non-specific CPP. 
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Table 4.1: Peptide sequences tested to improve HER2+ cell targeting and internalization of 
peptide conjugated nanoparticles. 
 
4.2.4. Peptide affinity testing of combination peptides conjugated to “single” PEGMA-PLGA 
nanoparticles 
At the determined concentration for PEGMA-PLGA nanoparticles thus far, the targeting affinity 
of L1 and the combination peptides and their scrambled combination sequence, C1, were 
assessed against both SKBR3 and MCF7 cells. From this first flow cytometry run tested against 
SKBR3 cells, L1 again shows about 20% FITC positive cells when incubated with L1 particles. 
Preliminarily, the increase in relative fluorescence of FITC, which was conjugated to the peptide 
N-terminus, was measured before switching to more reliable method of loading Rhodamine-B in 
the particle core. Comparatively, the TAT-L1 conjugated nanoparticles showed 43.9% FITC 
positive SKBR3 cells (Figure 4.6). This means that 23.7% more SKBR3 cells are able to bind 
with the added nanoparticles when the TAT-L1 sequence is conjugated to their surface and that 
there is greater affinity of SKBR3 cells to the TAT-L1 conjugated particles than those 
conjugated with the L1 sequence alone. As a positive control, TAT showed strong cell binding as 
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expected; this targeting is nonspecific across numerous cell types and would not specifically help 
target HER2+ as desired in this drug delivery system. The fluorescence measured from the 
control C1 conjugated nanoparticles was in line with that measured for the untreated cells, which 
indicates peptide sequence specificity of the combination peptides. While lower fluorescence 
intensity values or decreased particle-cell affinity was seen for the peptide conjugated 
nanoparticles tested against MCF7 cells, specifically those conjugated with L1, L1-TAT, TAT-
L1, and the positive control TAT, the specificity of the combination peptide TAT-L1 comes into 
question. Repeating these flow cytometry runs with the Rhodamine-B loaded nanoparticles and 
an additional non breast cancer cell source, such as fibroblasts or endothelial cells, will help to 
truly assess the peptide specificity. 
 
Figure 4.6: L1, combination peptides, and controls conjugated to PEGMA-PLGA ―single‖ nanoparticles (SNPs) 
tested against SKBR3 and MCF7 cells. Flow cytometry affinity testing of peptides conjugated to PEGMA-PLGA 
nanoparticles against HER2+ SKBR3 cells (top) and MCF7 cells (bottom). (A) Untreated cells, (B) L1 conjugated 
NP, (C) TAT-L1 conjugated NP, (D) L1-TAT conjugated NP, (E) TAT conjugated NP, and (F) C1 conjugated NP. 
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4.2.5. Chemistry strategy to improve nanoparticle targeting and uptake through novel 
Poly(ethylene glycol) Pentaerythritol triacrylate- Poly(lactic-co-glycolic acid) 
(PEGPET-PLGA) nanoparticles 
As mentioned in the introduction, the second strategy used to improve HER2+ breast cancer 
treatment involves modifying the initial PEGMA-PLGA chemistry.  The PEGMA-PLGA 
copolymer used thus far allows for conjugation of one peptide at the end of each chain. A novel 
copolymer called PEGPET-PLGA was synthesized in this work. With three times the C=C bonds 
available per polymer chain through the reaction with pentaerythritol triacrylate, this 
significantly increases the possible peptide presentation on the nanoparticles‘ surface. The 
PEGPET-PLGA copolymer was synthesized first by modifying PEG to have a –COOH end 
group followed by two Steglich Esterification reactions (Figure 4.7). The synthesis of this 
original polymer and the chemical structure that was expected was confirmed using 
1
H NMR and 
FTIR analysis through assignment of the chemical groups of the polymer components (Figure 
4.8). Through gel permeation chromatography (GPC), the number average molecular weight 
(Mn) was found to be 31,463 g/mol. With this copolymer developed, PEGPET-PLGA was used 
to fabricate nanoparticles through the same double emulsification process as the PEGMA-PLGA 
particles. Based on the copolymer structure with multiple functional groups dangling at one 
chain end, these particles were called ―palm-tree‖ nanoparticles (PNPs) or PEGPET-PLGA 
nanoparticles. PEGPET-PLGA nanoparticles showed good spherical morphology through SEM 
imaging and were found to be on the same scale size-wise as the SNPs, with an average diameter 
of 543.5 nm measured through DLS (Figure 4.9). 
   
96 
 
 
Figure 4.7: Reaction scheme for PEGPET-PLGA copolymer synthesis. (A) Two-step synthesis of PEGPET and (B) 
Complete copolymer synthesis of PEGPET-PLGA. 
 
Figure 4.8: Confirmation of PEGPET-PLGA copolymer synthesis through chemical analysis. (A) Labeled structure 
of PEGPET-PLGA copolymer, (B) 
1
H NMR of PEGPET and PEGPET-PLGA, and (C) FTIR of all synthesis 
components. 
 
   
97 
 
 
Figure 4.9: Imaging and size evaluation of PEGPET-PLGA nanoparticles (PNPs). SEM was used to visualize 
PEGPET-PLGA nanoparticles (left) and dynamic light scattering (DLS) was used to determine the mean particle 
diameter size. Scale bar=1µm. 
 
4.2.6. Peptide affinity and dosage testing of “palm-tree” PEGPET-PLGA nanoparticles 
Just as with the PEGMA-PLGA nanoparticles, flow cytometry was used to quantify the degree to 
which cell targeting takes place as well as settle on an optimal dose based on effect of increasing 
doses on cell viability. Using the PEGPET-PLGA polymer, nanoparticles were again fabricated 
from a w/o/w double emulsion process. L1 conjugated PEGPET-PLGA nanoparticle 
concentrations were assessed as the ―first pass‖ prior to testing nanoparticles conjugated with the 
novel combination sequences described in the previous section.  Peptide affinity was assessed by 
again measuring relative fluorescence as particle-cell binding occurs. From this early testing, 
nanoparticle concentrations ranging from 0.5 mg/mL down to 0.0625 mg/mL were assessed 
(Figure 4.10). While this testing is being repeated with the Rhodamine-B dye, this experiment 
gave insight into an optimal PEGPET-PLGA nanoparticle concentration of 0.25 mg/mL. At the 
dose of 0.5 mg/mL cell viability began to decrease significantly for particles fabricated with the 
PEGPET-PLGA copolymer, where at 0.25 mg/mL, cell viability was in line with the cell 
viability of the untreated cells (currently cannot access figure). This increase in fluorescence 
intensity for the PNPs at their optimal concentration shows a 27.3% increase in particle-cell 
   
98 
 
binding over the SNPs at their optimal concentration (although based on a modified particle 
formulation with loaded Rhodamine-B). This is supportive of the hypothesis regarding increased 
peptide presentation on the nanoparticle surface because not only do the PEGPET-PLGA peptide 
conjugated nanoparticles bind more cells, but a lower concentration of the PNPs is necessary to 
achieve this compared to optimal concentration of the SNPs. This experiment is indicative of cell 
surface binding and possible internalization that will be confirmed through future cell viability 
testing with drug loaded nanoparticles, where increased cell death will be indicative of 
nanoparticle uptake. These repeated results are promising and show the intended benefit of 
introducing the novel PEGPET-PLGA copolymer chemistry. Peptide affinity testing remains 
with the Rhodamine-B loaded formulations at the optimal doses found for both the SNPs and 
PNPs. The remaining combination peptides and the appropriate control sequences will be tested 
against the target SKBR3 cells and MCF7 negative control cells. The aims are to determine 
whether (1) L1 specificity remains in the combination sequences, (2) the addition of the CPP 
TAT sequence leads to increased cell death in a cell viability test with loaded DOX HCl 
chemotherapeutic drug in the nanoparticles‘ core, and (3) increased peptide presentation on the 
PNPs contributes to increased cell death compared to the SNPs. 
 
Figure 4.10: Flow cytometry affinity and dose testing of L1 conjugated PEGPET-PLGA ―palm-tree‖ nanoparticles 
against HER2+ SKBR3 cells. (A) Untreated cells, (B) Cells tested at a particle concentration of 0.5 mg/mL, (C) 
Cells tested at a particle concentration of 0.25 mg/mL, (D) Cells tested at a particle concentration of 0.125 mg/mL, 
and (E) Cells tested at a particle concentration of 0.0625 mg/mL. 
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4.3. Conclusion 
When used to treat diseases such as prevalent HER2+ breast cancer, drug loaded nanoparticles 
with targeted peptide ligands are beneficial for more closely treating this disease and reducing 
the systemic effects of the loaded drugs. The L1 peptide previously identified was used in this 
work to examine its utility in a drug delivery system with a suitable peptide spacer/linker of 2 
kDa PEG. On top of this initial testing, nanomaterial strategies were developed to further 
evaluate how targeting and internalization could be improved. Preliminary testing with the added 
TAT CPP peptide shows promise through flow cytometry, although questions remain with 
regards to the specificity imparted by the L1 peptide. Most importantly, an innovative PEGPET-
PLGA chemistry was synthesized, analyzed, and investigated to determine if increased cell 
targeting and uptake can be achieved. Comparing the results thus far, the effect of increased 
peptide presentation was shown as anticipated. With completed results from these two strategies, 
future in vitro remains to complete the conclusion of this work and truly analyze this 
nanoparticle drug delivery system. 
 To complete in vitro testing, quantification of the actual amount of peptide on the PNPs 
surface compared to the LNPs will be done using a Quantitative Colorimetric Peptide Assay kit. 
Next, the peptide affinity testing at the optimal doses for LNPs and PNPs will be completed for 
all of the peptide conjugated nanoparticles as begun in this dissertation. Finally, in vitro cell 
viability or Live/Dead testing will help determine the degree to which nanoparticles are 
internalized with the different peptide sequences conjugated to the nanoparticle surface, and 
whether the addition of the TAT sequence to the combination peptides helps with internalization 
and also allows for the maintenance for L1 specificity to HER2+ cells. To do this, DOX HCl will 
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be loaded into the nanoparticles and those that enter the cell will lead to increased cell death, as 
opposed to particles that only successfully attach onto the cell surface and are not able to release 
the loaded cytotoxic agent inside the cells. The flow cytometry and cell viability experiments 
against target HER2+ SKBR3 cells, control HER2- MCF7 cells, and an additional control cell 
source such as fibroblasts will complete this story and help confirm the hypotheses for this 
nanoparticle HER2+ targeting and internalization work.   
 
 
4.4. Experimental Section 
4.4.1. Materials 
Succinic anhydride, 99%, pentaerythritol triacrylate, triethylamine, 99%, Rhodamine B, 
fluorescein isocyanate isomer I (FITC), Tris(2-carboxyethyl)phosphine hydrochloride, silica gel 
(60Å, 230-400 mesh particle size), sand (50-70 mesh particle size), anhydrous sodium carbonate, 
sodium bicarbonate, 2 mL clear glass GPC vials and caps, and acryloyl chloride were all 
purchased from Sigma Aldrich (St. Louis, MO). Solvents: methylene chloride, tetrahydrofuran, 
methanol, acetone, ethyl ether anhydrous, and dichloromethane, 99.8% extra dry over molecular 
sieve were purchased from Fisher Scientific/Acros Organics (Hampton, NH). Fetal Bovine 
Serum (FBS), phosphate buffer saline (PBS) pH 7.4, McCoy‘s 5A cell medium and Penicillin-
Streptomycin (P/S) were purchased from ThermoFisher Scientific. Polyethylene glycol 1000 and 
2000 were purchased from Millipore Sigma (Burlington, MA) and polyethylene glycol 10,000 
was purchased from Fluka (currently Honeywell Morristown, NJ). Resomer RG 503 H Poly 
(D,L-lactide-co-glycolide) (PLGA) polymer was purchased from Boehringer Ingelheim, 
currently sold through Millipore Sigma. N‘N-Dicyclohexylcarbodiimide, 99% (DCC) and 4-
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(Dimethylamino)pyridine, 99% were purchased from Alfa Aesar (Haverhill, MA). 1M Tris-HCl 
pH 8.0 buffer was purchased through Invitrogen (Carlsbad, CA). Synthetic peptides used in this 
work were ordered at crude purity from GenicBio Limited (Shanghai, China). ProLong Gold 
Antifade Reagent with DAPI was purchased through Cell Signaling Technology. PTFE 
membrane syringe filters (13 mm diameter) with 0.45 µm pores were purchased from Thomas 
Scientific. SKBR3 and MFC7 cells were generously donated from Dr. SuHe Wang‘s laboratory 
in the Department of Medicine at the University of Michigan (originally purchased from ATCC). 
Doxorubicin hydrochloride for injection, USP was purchased from the University of Michigan 
Health System pharmacy (distributed from Mylan). 
 
4.4.2. Synthesis of Poly(ethyelene glycol) methacrylate spacer polymer 
Copolymers of PEGMA-PLGA were synthesized with three different lengths of poly(ethylene 
glycol) (PEG) to determine the appropriate spacer lengths for peptide conjugated nanoparticle 
experiments. To begin, PEGMA was first synthesized by reacting PEG with acryloyl chloride 
(AC) at a molar ratio of 1.1:1 PEG:AC in the presence of triethylamine under nitrogen gas in 
10% weight/volume anhydrous dichloromethane (DCM) for 24 hours. AC was added slowly and 
left to react while spinning in an ice bath. Reaction was purified by completely removing DCM 
solvent using rotovap, resuspending the polymer in fresh methylene chloride solvent, and 
washing three times with 10% sodium bicarbonate solution to remove unreacted AC. PEGMA 
polymer was precipitated in cold ethyl ether, collected, and dried under vacuum for two days.   
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4.4.3. Synthesis of Poly(ethyelene glycol) methacrylate- Poly(lactic-co-glycolic acid) (PEGMA-
PLGA) linear copolymer 
The complete PEGMA-PLGA linear copolymer was synthesized through a standard Steglich 
Esterification reaction. To carry this out, the PEGMA polymers previously synthesized were 
reacted with commercially bought PLGA polymer in a 3:1 molar ratio of PEGMA:PLGA. The 
reaction was carried out under nitrogen gas in anhydrous DCM and DCC and DMAP were added 
while the reaction was spinning under ice. The reaction was left to proceed for 24 hours. 
Following this, the reaction was filtered to remove any salt byproducts, precipitated in cold ethyl 
ether, and washed with methanol to remove any unreacted PEGMA polymer. The copolymer 
was filtered once more, collected, and left to dry under vacuum for two days.  
 
4.4.4. Synthesis of polyethylene glycol- pentaerythritol triacrylate (PEGPET) polymer 
Synthesis of the PEGPET polymer takes place through a two-step procedure. To begin, PEG 
2000 is reacted with succinic anhydride (SA) in a 1:1.3 ratio of PEG:SA to form PEG-COOH. 
This reaction takes placed under nitrogen in 10% weight/volume of tetrahydrofuran in the 
presence of triethylamine as a catalyst. This reaction is left to react for 24 hours after which the 
solvent is dried completely using a rotovap and the polymer is reconstituted in DCM. The 
reaction is filtered two times to remove any unreacted SA, precipitated in cold ethyl ether, 
collected, and dried under vacuum for two days. Once the PEG-COOH polymer is completely 
dried, it was reacted through a Steglich Esterification reaction with pentaerythritol triacrylate 
(PET) in a 1:3.3 ratio of PEG:PET. This reaction took place under nitrogen protection in 10% 
weight/volume anhydrous DCM with DCC and DMAP added slowly while spinning in ice. After 
reacting for 24 hours, the reaction was filtered to remove any salt byproduct that formed, put on 
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a rotovap to completely remove the DCM solvent, and resuspended in water to filter out the 
unreacted pentaerythritol triacrylate. After filtering, the polymer was lyophilized. The polymer 
was further purified through a gravity column packed with sand and silica gel with a running 
solvent of 15:85 of ethyl ether:DCM (500mL) followed by a running solvent of 15:85 
methanol:DCM (1200mL) was used.  
 
4.4.5. Synthesis of Poly(ethyelene glycol) pentaerythritol- Poly(lactic-co-glycolic acid) 
(PEGPET-PLGA) copolymer 
The complete PEGPET-PLGA copolymer was synthesized through a second Steglich 
Esterification reaction. To complete this, the previously synthesized PEGPET polymer was 
reacted with commercially bought PLGA polymer in a 3:1 molar ratio of PEGPET:PLGA. The 
reaction was carried out under nitrogen gas in anhydrous DCM, adding the DCC and DMAP 
solution while the reaction was spinning under ice. The reaction was left to proceed for 24 hours. 
Following this, the solvent was dried completely using a rotovap and resuspended in fresh DCM 
(100mL). Water (20mL) was added and using a separatory funnel, the reaction was washed three 
times. After washing, the polymer was precipitated in cold ethyl ether, collected, and dried under 
vacuum for two days. 
 
4.4.6. NMR Observation 
1
H spectra of the polymers developed in this work were recorded with a Varian Inova 500 NMR 
instruments operating at 500 MHz at room temperature using deuterated dimethyl sulfoxide 
(CD3)SO for the PEGMA polymer and deuterated chloroform (CDCl3) for the PEGPET and 
PLGA block copolymers.  
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4.4.7. Measuring molecular weight using gel permeation chromatography (GPC) 
Molecular weights of the copolymers were measured using gel permeation chromatography on a 
Shimadzu GPC system. Samples were prepared at a concentration of ~20 mg/mL in 
tetrahydrofuran and filtered using a 0.45 µm PTFE syringe filter into 2 mL GPC vials. Samples 
were run at a flow rate of 1 mL/min and were run through a refractive index detector. Analysis 
was done using Shimadzu GPC postrun software to determine the number average molecular 
weight (Mn) and/ or the weight average molecular weight (Mw).   
 
4.4.8. Fabrication of PEGMA-PLGA and PEGPET-PLGA nanoparticles 
PEGMA-PLGA and PEGPET-PLGA nanoparticles were fabricated through standard 
water/oil/water (w/o/w) double emulsion processes. Preliminarily, ratios of commercial PLGA 
and the synthesized polymers were tested to determine the ideal ratio for peptide conjugation, 
drug loading/ drug release, and to prevent particle agglomeration. From this, the ratio of 0.4g of 
commercial PLGA and 0.1g synthesized copolymer was determined. 5 weight percent of 
polymer was dissolved into DCM. The small water phase, depending on the testing being 
performed, can be DI water (for flow cytometry), Rhodamine B at a concentration of 1mg/mL 
(confocal microscopy), or varying concentrations of doxorubicin hydrochloride (DOX HCl) (for 
cell viability testing). The first emulsion was carried out by combining 100uL of the small water 
phase and 1mL of the polymer (oil) phase and mixed with a probe sonicator for 10 seconds on 
power 10. Following this, the first emulsification was slowly dripped into 20mL of a larger water 
phase of 1.0% poly(vinyl alcohol) (PVA) and mixed using the probe sonicator for 15 seconds 
following the complete addition of the first emulsion. The particles were then left to spin on a hot 
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plate for 3 hours to allow sufficient time for the DCM solvent to evaporate. Particles were then 
centrifuged for 6 minutes at 12,000 RPM and washed 2-3 times, collected, and lyophilized.   
 
4.4.9. Fluorescein isocyanate (FITC) labeling of N-terminus peptides 
Peptides were labeled by combining 3 mg FITC to a solution of 50 mg peptide/mL into 
carbonate-bicarbonate buffer (CBB) pH. 9.2. CBB stock was prepared by preparing 0.2 M 
solution of anhydrous sodium carbonate (1) and 0.2 M solution of sodium bicarbonate (2). 4 mL 
of the carbonate solution (1) is combined with 46 mL of bicarbonate solution (2), and the 
solution is brought up to 200 mL through the addition of deionized water. FITC is dissolved in 
the minimum volume (~0.5 mL) of acetone prior to adding to the buffered peptide solution. 
Reaction is left to stir for 24 hours under ice. Following this, peptides are dialyzed until excess 
FITC is removed and subsequently lyophilized to use.  
 
4.4.10. Conjugating peptides to PEGMA-PLGA and PEGPET-PLGA nanoparticles 
After particles were fabricated, peptides were then conjugated to the nanoparticle surfaces. 
Through a thiol-ene based Michael addition reaction, possible through cysteine-terminated 
synthetic peptides (C-terminus), facile reactions were carried out. To do this, nanoparticles, 
peptide, and Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) catalyst are reacted in a 
[1]:[5]:[2.5] ratio for 2 hours in 1M Tris-HCl pH 8.0 buffer (25 mg nanoparticles in 3mL of 
buffer). After 2 hours, particles were centrifuged, washed twice, and lyophilized. Prior to in vitro 
experiments, nanoparticles are sterilized using ethylene oxide (EtO) gas for 12 hours and aired 
out.   
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4.4.11. Fourier-transform infrared spectroscopy (FTIR) analysis 
FTIR was performed for the components of the new copolymer, PEG-COOH and PEG-PET, and 
complete PEGPET-PLGA copolymer after they were all dried under vacuum. Polymers were run 
on a Thermo-Nicolet IS-50 bench-top FTIR instrument. Background and sample scans were run 
at the following conditions: resolution of 1.0 cm
-1
, 32 scans each, and run at a spectral range of 
4000 cm
-1
 to 1000 cm
-1
 recording the % Reflectance.  
 
4.4.12. Scanning Electron Microscopy Observation 
Nanoparticles were imaged using a scanning electron microscope. To do this, the particles were 
sputter-coated with gold for 90 seconds in a Denton Desk II sputter coater. Imaging was done at 
5 kV with a JEOL-7800FLV SEM at various magnifications. Size and particle architecture was 
assessed using this technique. 
 
4.4.13. Measuring size distribution through Dynamic Light Scattering (DLS)  
The particle size of the PEGMA-PLGA and PEGPET-PLGA nanoparticles were measured by 
dynamic light scattering using a DelsaNano C, Beckman Coulter particle size analyzer. The 
mean diameter and size distribution of the minimum amount of particles necessary in suspension 
were measured at 25°C in PBS pH 7.4. 70 scans were performed during each run of the 
instrument.  
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4.4.14. Confocal imaging and testing of PEGMA spacer on PEGMA-PLGA peptide conjugated 
nanoparticles 
Nanoparticle confocal imaging and in vitro cell uptake experiments were performed to test the 
effect of different PEGMA spacer lengths by visualizing particle uptake using confocal 
microscopy. To do this, Rhodamine B loaded nanoparticles were fabricated as previously 
described with 1 kDa, 2 kDa, and 10 kDa molecular weight PEG. Peptides were also conjugated 
to the nanoparticle surfaces as previously mentioned. SKBR3 cells were seeded in a 24-well 
plate on a glass cover slip (14 mm diameter) with a seeding density of 10,000 cells/ well with 
McCoy‘s 5A medium modified with 15% FBS and 1% P/S. After seeding the cells for 24 hours, 
300 µL of sterilized particles with and without peptide were added at a concentration of 2 
mg/mL to each well. Cells and particles were incubated for 4 hours and subsequently washed 
twice with PBS pH 7.4, stained with ProLong Gold Antifade Reagent with 4‘6-diamidino-2-
phenylindole (DAPI) to stain the cell nuclei, and imaged. Overlap with the cell nuclei (blue 
DAPI) and nanoparticle (red Rhodamine) appear as a purple color in confocal microscopy, 
indicative of nanoparticle attachment and/or uptake into the cell after extensive washing. The 
laser parameters, intensity and gain, were adjusted using control cells with no particles and kept 
constant to image particle-treated cells without changing the laser parameters. Quantification 
analysis was done using the colocalization and cell counting functions found in ImageJ. 
 
4.4.15. Peptide-conjugated particle affinity testing to target HER2+ SKBR3 cells 
Targeting affinity was tested using flow cytometry. To do this, cells were grown to 80% 
confluency in a T-75 flask, digested with 0.25% Trypsin-EDTA, and then washed with fresh 
DMEM complete medium for cell recovery. Cells were then blocked with 1% bovine serum 
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albumin (BSA) in PBS at 4°C. Samples (0.5 x 10
-6 
cells) were incubated with peptide conjugated 
nanoparticles loaded with Rhodamine-B dye for 1h at room temperature in the dark. Samples 
were then washed three times and suspended in 0.1% BSA/PBS and analyzed with an Accuri C6 
Flow Cytometer (BD Biosciences, San Jose, CA).  
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Chapter 5. Conclusions and Future Directions 
 
5.1. Summary 
This dissertation focused on manipulating and evaluating novel materials and components for 
tissue engineering and drug delivery applications. These biomaterials, which are made to interact 
with cells on the nanoscale, were specifically modified to change the materials‘ 
functionalization, surface area/processability, nanofeatures, and mechanical properties. 
Materials, whether hydrogels or polymeric nanoparticles, can be made to better perform if 
characteristics of the material are in line with the nanoscale components they are mimicking or 
helping to support. By tailoring these nanotechnology-derived biomaterials and modifying 
physical and chemical components such as the crosslinking density, crosslinker length, porous 
architecture, and ligand presentations, the two novel materials presented in this work were made 
suitable for their respective aims.  
 To this end, the hydrophobic monomer 2-methylene-1,3,6-trixococane (MTC) was 
crosslinked with Poly(ethylene glycol) diacrylate at various molecular weights and at varying 
concentrations to characterize its materials‘ properties and ultimately evaluate its 
biocompatibility as a hydrogel for future use in tissue engineering applications (Chapter 2) and 
evaluate its performance as a hydrogel material for drug delivery use (Chapter 3). With its 
chemical structure nearly identical to that of the FDA-approved polymer PCL, it was presumed 
that it would be non-toxic and show good biocompatibility, especially when crosslinked as part 
of a water-absorbing hydrogel. The chemical structure and nature of MTC made it interesting to 
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explore for these biomaterials applications because it was hypothesized based on its chemistry 
that it could function as the main component in a degradable, tunable, and processable hydrogel 
system. Degradability was considered the greatest advantage and one of the driving factors for 
pursuing the use of this monomer due to the ester linkage formed upon radical ring-opening 
polymerization, allowing the material to undergo hydrolysis. Overall in Chapter 2, it was 
observed that the swelling and degradation properties of the MTC gels/hydrogels were dictated 
by the hydrophilic-hydrophobic balance of the samples. The hydrophilic-hydrophobic balance 
was varied by changing the crosslinker length and changing the crosslinker mole concentration 
with respect to moles of MTC monomer. Uniquely, the increase in hydrophilicity as crosslinker 
length and concentration were increased in the samples contributed to an uncharacteristic 
hydrogel trend which was that the degree of swelling increased as crosslinker concentration was 
increased. Additional advantages included the: (1) one-pot synthesis that was possible through 
the monomer existing in a liquid state at room temperature and being miscible with the PEGDA 
crosslinker upon heating, and (2) processability due to the absence of water or organic solvent 
during processing that allowed for a larger interconnected, porous network to be fabricated 
through the sugar sphere porogen process. In Chapter 3, the tunability of this gel/hydrogel 
system was again shown, specifically with respect to the different drug release kinetics that can 
be achieved as crosslinker concentration, crosslinker length, solution pH, and drug type are 
changed. Taken together, these properties and advantages produced low and high swelling and 
degradable scaffolds and drug delivery vehicles. For tissue engineering, compositions with low 
to moderate swelling showed good biocompatibility as cells were not as isolated within the MTC 
scaffold and showed greater numbers in cell viability assays presumably due to better cell 
attachment, an advantage of hydrophobic scaffolds. As mentioned in the introductory chapter, 
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hydrophilic scaffolds/hydrogels like PEG are inherently bioinert and often used to prevent cell 
and protein adhesion, which is due to their hydrophilicity. The drug delivery testing showed the 
MTC samples to be a suitable drug delivery system for hydrophobic drugs with controlled, even 
release showed over a long-term study. Drug delivery systems for hydrophobic drugs are in 
increased demand in the biomaterials field as over 40% of drugs on the market and many in the 
research phase are hydrophobic
(138)
. The model protein tested showed more sustained release 
compared to the rapid release model small molecule hydrophobic drug tested, although the 
protein release curves were characterized by a greater burst release and drug concentration 
dependent behavior compared to the small molecule hydrophobic drug tested. The tunability of 
this MTC gel/hydrogel material as far as varying the crosslinker and selecting for a degree of 
swelling, degradation rate, specific modulus, and/or drug release kinetic, sets the stage for its 
future utility in numerous nanobiomaterial applications. Some of these specific early applications 
are highlighted in the future works section.   
 Similarly, in Chapter 4, polymeric nanoparticles were tailored for their particular 
application, namely improved breast cancer cell targeting and internalization. A copolymer of 
PEGMA-PLGA was first synthesized to fabricate nanoparticles that were used to assess peptide 
conjugation and HER2+ SKBR3 cell targeting and binding, specifically for the HER2+ targeting 
L1 peptide identified, when attached onto a nanoparticle surface. SKBR3 cell targeting was 
achieved with 20% of tested cells achieving nanoparticle-peptide binding. This confirmed that 
the L1 peptide could perform when conjugated to a polymeric nanoparticle surface. Following 
this, combination peptides were developed with the added CPP TAT sequence to determine how 
the L1-TAT and TAT-L1 conjugated particles perform compared to particles with only the L1 
peptide sequence. Through work done with a collaborator, early flow cytometry experiments 
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show increased binding of LNPs conjugated with the TAT-L1 peptide compared to LNPs 
conjugated with L1 alone. The L1-TAT conjugated LNPs showed similar binding affinity to 
SKBR3 cells as L1 conjugated LNPs and may not enhance HER2+ targeting. The remaining in 
vitro cell viability assays help determine the extent of peptide affinity, selectivity, and 
internalization. The hypothesis regarding an increase in peptide density on the nanoparticle 
surface was then evaluated. A novel copolymer chemistry using pentaerythritol was developed to 
theoretically triple the amount of peptide that could be conjugated to the nanoparticle surface.    
Through peptide affinity testing again using flow cytometry, the nanoparticles fabricated from 
this PEGPET-PLGA copolymer conjugated with the L1 peptide show an increase in cell binding, 
which is displayed by an increase in fluorescence intensity compared to the PEGMA-PLGA 
nanoparticles conjugated with the L1 peptide. Not only was increased cell binding of the PNPs to 
HER2+ SKBR3 cells shown, but a lower PNP concentration was utilized to achieve this 
compared to the optimal LNP concentration found and tested. Through these manipulations, the 
promise of enhanced HER2+ cell targeting is supported by this work thus far and the remaining 
in vitro experiments and future in vivo work will help analyze the internalization ability and 
selectivity of this nanoparticle drug delivery system. 
 
5.2. Future Directions 
5.2.1. 2-methylene-1,3,6-trioxocane (MTC) for specific tissue engineering and drug delivery 
applications 
Throughout this work, the MTC gels/ hydrogels were characterized and evaluated for potential 
tissue engineering and drug delivery applications. On the tissue engineering front, the different 
formulations were evaluated with regards to biocompatibility to show that after multiple days of 
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cell seeding, cells continued to be viable, especially on more gel-like substrates that do not swell 
significantly and have elastic moduli in the range of 100 kPa. The gel/hydrogels that showed the 
best biocompatibility include the 575 Da and 2 kDa 1% PEGDA crosslinked MTC formulations. 
Keeping with the one-pot reactions used for gelation, one of the first goals to set the pace for 
future tissue engineering use is to determine if adhesion factors such as the RGD adhesion 
peptide motif and others could be incorporated into the reaction, taking advantage of the atypical 
properties of the monomer (liquid state) and gelation process (solvent-free). This has been 
preliminarily evaluated. 1% RGD peptide was added into the 2 kDa 1% MTC-PEGDA 
formulation and fabricated into 3D interconnected, porous scaffolds as discussed in the 
dissertation. By implanting these gel scaffolds subcutaneously into 4 pockets on the back of 
C57BL/6 mice, performed by Ma Lab colleague Zhen Zhang, native cells were left to infiltrate 
the substrates over two weeks. Through histological sectioning and Haemotoxylin and Eosin 
(H&E) staining performed at the histology core at the University of Michigan School of 
Dentistry, 2 kDa 1% gels with RGD incorporated showed cell infiltration throughout the gel and 
within the scaffold pores while the other groups tested showed cells only on the scaffold 
perimeter and empty pores within the gel (Figure 5.1). This gel with RGD also showed evidence 
of blood vessel formation just as in the 575 Da PEGDA control, which is a very rigid, 
nondegradable scaffold. Future projects within the lab hope to build on this experimentation and 
system, specifically to regenerate adipose and other soft tissues within the laboratory. Based on 
the measured modulus values for the MTC gels, soft tissue regeneration as opposed to hard tissue 
regeneration seems to be a suitable application for the material over overall; and this novel 
scaffolding material can benefit future soft tissue regeneration projects in the lab. Previously, our 
laboratory has been well versed in scaffolds made from more crystalline polymers such as 
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poly(L-lactic acid) (PLLA), which has shown better utility for stiffer tissues such as bone and 
cartilage. Using these PLLA scaffolds, I have previously explored adipose-derived stem cells 
(ADSCs) growth and development into adipose tissue with and without added factors such as 
insulin conjugated to the scaffold surface as a supplemental project. Exploring how adipose 
tissue growth responds on the MTC gels with a modulus closer to native adipose tissue than the 
PLLA scaffold previously used for this work is expected to show enhanced results upon testing. 
 
Figure 5.1: H&E staining of in vivo gels following subcutaneous implantation in mice for 2 weeks. 
 
A major way in which this MTC tissue engineering work can be expanded is to test this 
material as a driving component of a specific tissue engineering system. A project currently 
being explored as a collaboration between myself (materials preparation and sterilization), 
Renato Navarro (monomer synthesis), and Dr. Younghun Jung (cell seeding and biological 
experiments) seeks to determine how MTC scaffolds can be used to improve the development of 
characteristic gland-like structures in both mammary and prostate cells grown from CXCL12γ-
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overexpressing epithelial cells. Collagen gel has been used previously to attempt to grow these 
cells in an in vivo xenotransplantation animal with limited success and ability to recover the 
gland-like structures of these two cell types. In this work, Heparin is incorporated as an adhesion 
molecule and to support differentiation of the two cell types used into the fabricated 3D 
interconnected, porous substrates. Thus far, proliferation was evaluated for MCF10A breast 
epithelial cells and PNT2 prostate epithelial cells. The 2 kDa 0.25% and 1% MTC samples with 
Heparin show great promise with regards to cell proliferation, especially when compared to the 
MTC gels without heparin (vehicle) and collagen gels used as the gold standard in these studies 
(Figure 5.2). Future experiments will continue using Heparin-MTC gels to evaluate the 
differentiation and gene expression of these two cell types with the goal of evaluating in vivo 
gland structure.   
 
Figure 5.2: Proliferation results for CXCL12γ- mediated MCF10A and PNT2 epithelial cells after 3 days on various 
substrates including 3D porous MTC gels with and without heparin. Data is presented as mean ± SD (Student‘s t-
test). (Data collected and prepared by Dr. Younghun Jung). 
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On the drug delivery application side of this MTC hydrogel material, as mentioned in 
Chapter 3, modeling can be used to determine the drug release mechanism. By solving for the 
diffusion coefficients and meshing this with the release kinetics found, more can be understood 
about this drug delivery system and the factors at play. Additional kinetic models can also be 
looked into such as the Higuchi, Hixon-Crowell, and Korsmeyer-Peppas models to help clarify 
the drug delivery kinetics found in this MTC drug delivery system. Nevertheless, much 
information was garnered from the work presented about drug release from the MTC hydrogels 
with respect to changes in crosslinker concentration, crosslinker molecular weight, and drug 
type. MTC hydrogels for drug release are currently being applied to projects within the Ma Lab, 
including as a delivery system for exosomes. This work is a collaboration between myself 
(materials fabrication) and labmates Renato Navarro (monomer synthesis) and Ming Guan 
(biological experiments). Exosomes are vesicles, composed of lipid bilayers, that are secreted by 
cells and range in size from 30-100 nm, slightly larger than the BSA model protein loaded
(180,181)
. 
These vesicles are important in cell-cell communication and have been found to contain genetic 
information and factors that help promote cell growth and function, and they are particularly 
being applied to the field of tissue engineering. Exosomes isolated from bone marrow stromal 
cells (BMSCs) have been concentrated and loaded into 2 kDa 1.0% gels, as a novel release 
system to aid in the growth of nucleus pulposus cells. Preliminarily, the release of exosomes 
from MTC hydrogel samples has been explored for 30 days thus far, and found to mimic the 
release behavior of BSA protein (Figure 5.3). This system will be evaluated compared to 
traditional polymeric nanoparticles to determine a suitable drug release system for this 
regeneration goal. 
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Figure 5.3: Cumulative exosome release from 2 kDa 1% MTC gels over 30 days. All values reported as mean ± SD 
(n=3). Error bars are smaller than size of markers on graph. (Data collected by Ming Guan). 
 
The tissue engineering and drug delivery applications presented in this dissertation and 
being pursued as future works with this material apply the MTC gels/hydrogels for separate 
applications. An ideal material within the larger field of biomaterials would be one that can be 
used as a simultaneous tissue engineering and drug delivery platform. From the analysis 
presented here, this is where the future utility of this material lies and would help satisfy two 
components of the tissue engineering triad presented in the introduction chapter: as a scaffolding 
material to support the growth of cells into tissues and organs and as a controlled delivery 
vehicle for the necessary biological factors to support tissue growth. Balancing how best to 
achieve this will need to be done by selecting an appropriate crosslinker concentration, selecting 
an appropriate crosslinker length, considering the growth factors or drugs that must be loaded, 
and considering the rate at which these agents should be released. Some give and take may be 
necessary to support both functions; however, from that data presented and the larger plan for 
this material, this is what is envisioned and how the material can be applied. The injectability 
will also need to be assessed for this simultaneous tissue engineering and drug delivery 
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application due to the addition of cells, which may be disrupted by the UV light used for 
gelation.   
Outside of the biomaterials scope of this dissertation, two additional future goals have 
been developed with respect to the MTC monomer. As previously mentioned, MTC is difficult to 
polymerize to high molecular weights using standard radical polymerization methods. Renato 
Navarro, a collaborator in the Ma Lab and the MTC work presented, has begun the chemistry 
work to make this process feasible. This is a great aim for this monomer and will open up more 
avenues for polymerized MTC use, including potential fabrication into tissue engineering 
scaffolds without the need for UV crosslinking. Another future work is creating the ―next 
generation‖ of the MTC ring monomer and characterizing this original monomer and its 
properties when crosslinked (i.e. swelling, degradation, and rheological properties). This 
monomer, which we have named ‗MQC‘ for the four oxygens in the ring structure, is expected to 
show good elastic properties and be more hydrophilic to MTC leading to an increase in its 
swelling and degradation properties. MQC synthesis, confirmation of structure and molecular 
weight, and analysis of crosslinked properties is currently underway for future publication at the 
time of this dissertation between myself and Renato Navarro.  
 
5.2.2. Future testing of “single” PEGMA-PLGA and “palm-tree” PEGPET-PLGA nanoparticles   
The best testing of a drug delivery system is in vivo in a clinically translatable animal model. A 
clinically translated model would be one that not only has the necessary disease presentation, but 
also has its own immune system intact rather than a knock-down of the immune system (nude 
model). This type of clinically relatable testing remains a future goal of this project through a 
collaboration with Prof. SuHe Wang‘s laboratory. Previous work in the Wang lab has developed 
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a transgenic mouse tumor model for HER2+ testing by inoculating mouse mammary cells 
engineered with human wild-type HER2 into C57BL/6 HER2 transgenic mouse
(182)
. This is the 
perfect model based on the HER2+ targeting of the initial L1 peptide sequence. Testing would be 
done through mouse tail-vein injection of the nanoparticles to observe (1) shrinkage of the tumor 
from initial size through successful delivery of the loaded drug into tumor cells and (2) 
specificity of the peptide conjugated nanoparticles by imagining the organs of the mouse and 
checking for red fluorescence, which is characteristic of the drug DOX HCl. This is an exciting 
future direction of this PEGMA-PLGA versus PEGPET-PLGA peptide conjugated nanoparticle 
testing.  
 
5.3. Thesis Conclusion 
The continued success and translation of tissue engineering and drug delivery research into the 
clinic depends on advances being continuously being made in the field of biomaterials. When 
considering the material-cell interaction and how cells respond to their environment, it is 
important to tailor materials‘ temporal and spatial properties and consider the influence of 
components on the nanoscale. This dissertation focuses on all of these factors and specifically 
applies them to meet the challenges found in two different areas, (1) hydrogel systems and (2) 
nanoparticle targeting and internalization. Advancements were made to the field of biomaterials 
by providing two novel materials, MTC gel/hydrogel and nanoparticles made from PEGPET-
PLGA chemistry, and a platform for their future applications.  
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Appendix A. Supplemental images to Hydrogels with Unique Swelling Properties as a 
Biomaterial for Tissue Engineering Application  
 
 
 
Figure A.1: NMR analysis of MTC monomer synthesis. 500 MHz NMR spectrum of 2-methylene-1,3,6-trioxocane 
(A) 
1
H spectrum and (B) 
13
C spectrum. 
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Figure A.2: FTIR analysis of MTC monomer synthesis. Fourier-transform infrared spectroscopy (FTIR) spectrum 
for MTC synthesis step 1 reaction and step 2 reaction.  
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Figure A.3: Complete panel of SEM images of gels/ hydrogels. Scanning electron microscopy of initial dry and 
swelled gel/hydrogels with varying crosslinker percent and length. 
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Figure A.4: Complete swelling test to decouple crosslinker molecular weight. Swelling tests further showing the 
effect of crosslinker concentration at varying crosslinker molecular weights. Concentrations tested are 2x (0.5% to 
1.0%) and 5x (0.5% to 2.5%). 
 
 
Figure A.5: In vitro biocompatibility testing through proliferation assay trends for porous gels/hydrogels seeded 
with ADSCs and DPSCs. (A) 2.5% scaffolds with ADSCs, (B) 2.5% scaffolds with DPSCs, (C) 1.0% scaffolds with 
ADSCs, (D) 1.0% scaffolds with DPSCs, (E) 0.25% scaffolds with ADSCs, and (F) 0.25% scaffolds with DPSCs. 
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Figure A.6: In vitro through SEM images of 1.0% porous gels/ hydrogels seeded with DPSCs. 
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Appendix B. Supplemental images to Delivery of Hydrophobic Small Molecule, 
Hydrophilic Small Molecule, and Protein Drugs from Novel 2-methylene-1,3,6-
trioxocane (MTC) Hydrogels 
 
 
Figure B.1: Linear zero-order curve fitting for Simvastatin release from 575 Da samples at pH 7.4. Fitting shown 
with burst release (top) and without burst release (bottom). Columns: (A) 1% crosslinked samples, (B) 2.5% 
crosslinked samples, (C) 5% crosslinked samples, (D) 7.5% crosslinked samples, and (E) 10% crosslinked samples. 
 
 
Figure B.2: Linear first order curve fitting for Simvastatin release from 575 Da samples at pH 7.4. Fitting shown 
with burst release (top) and without burst release (bottom). Columns: (A) 1% crosslinked samples, (B) 2.5% 
crosslinked samples, (C) 5% crosslinked samples, (D) 7.5% crosslinked samples, and (E) 10% crosslinked samples. 
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Figure B.3: Linear zero-order curve fitting for Simvastatin release from 8 kDa samples at pH 7.4. Fitting shown 
with burst release (top) and without burst release (bottom). Columns: (A) 1% crosslinked samples, (B) 2.5% 
crosslinked samples, (C) 5% crosslinked samples, (D) 7.5% crosslinked samples, and (E) 10% crosslinked samples. 
 
 
Figure B.4: Linear first order curve fitting for Simvastatin release from 8 kDa samples at pH 7.4. Fitting shown 
with burst release (top) and without burst release (bottom). Columns: (A) 1% crosslinked samples, (B) 2.5% 
crosslinked samples, (C) 5% crosslinked samples, (D) 7.5% crosslinked samples, and (E) 10% crosslinked samples.  
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Figure B.5: Linear zero-order curve fitting for Simvastatin release from 2 kDa samples at pH 7.4. Fitting shown 
with burst release (top) and without burst release (bottom). Columns: (A) 1% crosslinked samples, (B) 5% 
crosslinked samples, and (C) 10% crosslinked samples. 
 
 
Figure B.6: Linear first order curve fitting for Simvastatin release from 2 kDa samples at pH 7.4. Fitting shown 
with burst release (top) and without burst release (bottom). Columns: (A) 1% crosslinked samples, (B) 5% 
crosslinked samples, and (C) 10% crosslinked samples. 
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Figure B.7: Linear zero-order curve fitting for Simvastatin release from 2 kDa samples at pH 4.0. Fitting shown 
with burst release (top) and without burst release (bottom). Columns: (A) 1% crosslinked samples, (B) 5% 
crosslinked samples, and (C) 10% crosslinked samples. 
 
Figure B.8: Linear first order curve fitting for Simvastatin release from 2 kDa samples at pH 4.0. Fitting shown 
with burst release (top) and without burst release (bottom). Columns: (A) 1% crosslinked samples, (B) 5% 
crosslinked samples, and (C) 10% crosslinked samples. 
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Figure B.9: Linear zero-order curve fitting for BSA release from 575 Da samples at pH 7.4. Fitting shown with 
burst release (top) and without burst release (bottom). Columns: (A) 1% crosslinked samples, (B) 2.5% crosslinked 
samples, (C) 5% crosslinked samples, and (D) 7.5% crosslinked samples. 
 
 
Figure B.10: Linear first order curve fitting for BSA release from 575 Da samples at pH 7.4. Fitting shown with 
burst release (top) and without burst release (bottom). Columns: (A) 1% crosslinked samples, (B) 2.5% crosslinked 
samples, (C) 5% crosslinked samples, and (D) 7.5% crosslinked samples. 
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Figure B.11: Linear zero-order curve fitting for BSA release from 575 Da samples at pH 4.0. Fitting shown with 
burst release (top) and without burst release (bottom). Columns: (A) 1% crosslinked samples, (B) 2.5% crosslinked 
samples, (C) 5% crosslinked samples, and (D) 7.5% crosslinked samples. 
 
 
Figure B.12: Linear zero-order curve fitting for BSA release from 575 Da samples at pH 7.4. Fitting shown with 
burst release (top) and without burst release (bottom). Columns: (A) 1% crosslinked samples, (B) 2.5% crosslinked 
samples, (C) 5% crosslinked samples, and (D) 10% crosslinked samples. 
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Appendix C. Supplemental images to Targeting of HER2+ SKBR3 cells with Novel 
Conjugated Targeting Peptides on “Single” versus “Palm-tree” PEG-PLGA 
Nanoparticles 
 
 
Figure C.1: Flow cytometry of increased L1 conjugated PEGMA-PLGA particles against HER2+ SKBR3 cells 
negatively affects cell viability and leads to fluorescence oversaturation. 
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